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Abstract 
 
Background: Prescription opioids are powerful painkillers that are highly addictive and may 
result in death when taken at high doses or combined with alcohol or other drugs. A major risk 
factor for prescription opioid mortality is high dose prescribing, leading many state level 
organizations to adopt policies intended to discourage prescribing above a certain standardized 
dose, known as a Morphine Equivalent Daily Dose (MEDD) threshold. The values of these 
thresholds vary significantly by the states and organizations that set them, and are used in 
different types of policies to influence prescribing behavior. Despite the proliferation of these 
policies in recent years, little is known about the variability in these policies or their impact on 
prescribed dose. The objectives of this dissertation are to systematically identify and characterize 
state-level MEDD threshold policies and evaluate the impact of a subset of these policies on 
prescribed dose in workers’ compensation and privately insured populations. 
Methods: State-level MEDD threshold policies were systematically reviewed and verified 
against existing policy compilations and academic literature. For states where no policies were 
identified, at least one representative of a state health agency was contacted to confirm the 
absence of any MEDD threshold policy. Policies were independently double coded on the 
categories: state, agency/organization, policy type, effective date, threshold level, and policy 
exceptions. Next, two workers’ compensation guidelines identified in the review were evaluated 
using workers’ compensation claims data from a large, national insurer. Policies from nine 
additional states comprised of guidelines, rules/regulations, legislative acts, and passive alert 
systems were evaluated using a large, national sample of commercial claims data. For both 
claims analyses, an interrupted time series with comparison states design was utilized with 
average monthly MEDD as the primary outcome. Additional stratified analyses examined each 
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state policy individually and evaluated the policies separately by groups explicitly excluded by 
the policies (e.g., patients with cancer, acute pain diagnoses, or receiving end of life care) to 
determine if the policies were being targeted as intended. 
Results: As of June 2017, 22 states had at least one type of MEDD threshold policy, most 
commonly guidelines followed by prior authorization requirements, rules/regulations, legislative 
acts, claim denials, and alert system/automatic patient report. There was a wide range of 
threshold values (30-300 mg MEDD) with threshold levels generally decreasing over time. Most 
policies exclude some groups of opioid users, most commonly patients with terminal illnesses or 
acute pain. In the two states that passed workers’ compensation guidelines, guideline passage 
was associated with a 9.26 mg decrease in prescribed MEDD and larger decreases were observed 
in claimants with chronic, non-cancer pain. In the nine states which passed MEDD policies 
aimed at the general population, results were more mixed. Policies were associated with 15% 
lower odds of any opioid use, but no significant change in the odds of receiving high dose 
prescriptions, specifically and there was actually a slight increase in prescribed dose when the 
population was restricted to opioid users. Furthermore, changes in opioid use did not appear to 
be targeted towards intended groups of patients. 
Conclusions: This study finds that states have implemented a wide variety of MEDD threshold 
policies and there is little consensus as to threshold level or policy structure. In the context of a 
workers’ compensation population, passage of MEDD threshold guidelines was associated with a 
decrease in prescribed MEDD. However, MEDD threshold policies were not associated with a 
decrease in prescribed MEDD in a privately insured population. It is possible that guidelines 
targeted towards a specific population, e.g., injured workers, may be more effective than those 
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aimed at the general population. Future work should examine the impact of MEDD threshold 
policies in other contexts, including impacts on patient health. 
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Chapter 1. Introduction 
 
Nature and Burden of Prescription Opioid Morbidity and Mortality 
Opioid analgesics are powerful painkillers and an essential tool for managing patients’ pain. 
However, prescription opioids are also highly addictive and potentially fatal at high doses or 
when used in conjunction with alcohol or other drugs.1 While the past fifteen years have seen a 
marked decrease in motor vehicle deaths and homicides2 the number of overdose deaths from 
prescription opioids in the United States has doubled from 2002-2016.3 Overall, there were over 
14,000 deaths involving prescription opioids in 2016,3 or roughly 40 deaths per day. Over one 
million people went to the emergency room due to prescription opioid misuse in 20114 and over 
ten million Americans reported nonmedical use (use in a manner not intended by the prescriber) 
of prescription opioids in 2014.5  
 
Opioid overdoses are considered a type of poisoning injury and can be categorized as intentional 
(as a method of suicide) or unintentional. Although it is often difficult to ascertain whether a 
prescription drug overdose was intentional or unintentional, it is estimated that the rate of 
unintentional overdose of prescription opioids is approximately eight times the rate of intentional 
overdose.6 Unintentional injury is the leading cause of death for all age-groups 1-44 and suicide 
is the second leading cause of death for ages 15-34.7 Among unintentional injury deaths, 
poisoning is the leading cause of death, surpassing even motor vehicle deaths in recent years.8 
Opioid analgesics are less commonly used as a means for suicide, but are still of concern given 
their widespread availability.6 The most common types of painkillers involved in overdose 
fatalities are buprenorphine, fentanyl, hydromorphone, methadone, and oxycodone.9 While 
prescription opioids were the largest mortality contributor to the opioid epidemic until 2014, in 
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recent years, deaths from prescription opioids have been surpassed by the illicit opioid, heroin, 
and fentanyl, which can be used medically but is increasingly being illegally manufactured and 
sold.3 
 
Social and Political Context 
Prescription opioid abuse as a public health issue has a long and complex history. While, the 
issue of prescription opioid abuse has gained considerable attention in recent years, the problem 
is far from novel. Opioids, derived from the poppy plant, have been used to treat pain for 
thousands of years; they were thought to have been first used by the Sumerians around 3400 
BC.10 Morphine, which is still commonly used today, was developed in 1803 and a number of 
natural, semisynthetic, and synthetic opioid medications have been since developed.10 Since that 
time, there has been considerable tension between the recognized medical use of opioids to treat 
pain and the serious problems of addiction, overdose, and recreational use.10 The use of opioids 
in medicine grew during the 1800s, but with it grew the realization that opiates were physically 
addictive and could easily be abused.10 In the late 1800s and early 1900s, there were 
considerable international efforts to curb the improper use of opioids including development of 
therapies for the treatment of opioid addiction, stricter prescribing standards, and creation of 
new, less addictive formulations.11 In general, there was a growing sentiment that those with a 
history of substance abuse or addiction should not receive opioids, even following injury. 
However, in the late 1990s in the United States, views on pain management began to again 
change. Pain came to be known as “the fifth vital sign,” meaning that clinicians were expected to 
routinely take pain ratings and include pain management as part of comprehensive treatment.12 
There was also a growing recognition that a substantial proportion of patients were not receiving 
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adequate pain treatment.12 Research showed that pain was not only a symptom, but also had an 
independent effect on physical function and was worthy of treatment in and of itself.13,14 
Prescriptions of opioid analgesics for pain relief rose steadily along with prescription opioid-
related mortality.19  
 
As mortality from prescription opioids has increased in recent years, the view that the 
prescription opioid epidemic should be a top public health priority, has gradually gained 
acceptance. While drug overdoses, in general, were previously seen as belonging to the domain 
of law enforcement, the increase in the proportion of drug overdoses involving prescription drugs 
has led more people to view the issue as a matter of public health.15 Furthermore, there has been 
a greater realization that drug addiction is not just about the actions of an individual, but rather 
involves a complex interplay between the individual, the drugs, and the environment. 
Prescription opioid addiction and overdose deaths are also increasingly being viewed as 
iatrogenic issues, giving the medical establishment a stronger moral imperative and increased 
agency to act.16  
 
Epidemiology of Prescription Opioid Morbidity and Mortality 
The burden of the opioid epidemic is felt across age, race, gender, and socioeconomic status and 
each group faces a unique set of challenges. However, some groups have an especially high risk 
of morbidity and mortality. Opioid use and overdose differ by gender, but this relationship is 
complex. Females generally report greater pain sensitivity17 and more frequent occurrence of 
psychological distress,18 both of which are risk factors for prescription opioid misuse.1 Doctor-
shopping, a practice in which patients visit multiple doctors in order to receive more opioid 
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prescriptions, is also more common among women.1 Despite these relationships to several key 
risk factors, overall, males are at greater risk of misusing prescription opioids and have higher 
prescription opioid-related mortality, perhaps due to more frequent concurrent use of other drugs 
and alcohol.10 Age has a similarly complex relationship. Overall, older patients are more likely to 
receive opioids, tend to receive higher doses, and are more likely to receive overlapping 
prescriptions;19,20 however, younger individuals are more likely to use opioids nonmedically than 
older patients.21 Perhaps for this reason, those in middle age groups (35-54) tend to have the 
highest levels of prescription opioid mortality.22 Individuals who abuse alcohol and/or non-
opioid drugs, are white, and have a low income are also at an increased risk of opioid misuse, 
overdose, and mortality.10 Studies have suggested that residents of rural areas have higher rates 
of opioid related overdoses1,23 and nonmedical opioid use24 as compared to those in urban and 
suburban areas, but have fewer available addiction treatment resources.25,26 
 
Opioid Morbidity and Mortality among Chronic Pain Patients and Injured Workers 
Two populations of particular interest to researchers and policymakers are chronic pain patients 
and injured workers, both of whom are exposed to opioids through medical use. Individuals may 
experience chronic pain for a variety of reasons including previous traumatic injury, repetitive 
use injuries, or from complications of chronic conditions. Among chronic pain patients with 
long-term use of prescription opioids, psychiatric comorbidities and substance use disorders are 
extremely prevalent.27 Although the relationship between chronic pain, substance use, and 
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psychiatric comorbidities is complex, there is some evidence of reciprocal relationships between 
these domains.28,29  
 
Occupational health researchers and insurers have also become increasingly interested in 
prescription opioid addiction. Workers often initiate opioid use following an occupational injury 
and development of opioid addiction may delay return to work.30,31 Previous research has found 
opioid use to be very common in injured workers with around one-third of shoulder and back 
injuries receiving opioids and nearly half of those patients going on to become long-term opioid 
users (>3 months of continuous use).32 Furthermore, research suggests that opioid users in the 
workers’ compensation population are more likely to receive high doses and to become long-
term users than are opioid users in the general population.33 Injured workers generally receive 
medical care paid for by workers’ compensation claims, which can be a valuable source of 
information for researchers studying opioid prescribing practices in this population. 
 
Current Policies Addressing the Opioid Epidemic 
In response to the opioid epidemic, a number of initiatives have been undertaken at the local, 
state, and national levels. Prescription drug monitoring programs (PDMPs) are one such type of 
initiative enacted at the state level. PDMPs collect prescribing data in order to combat doctor 
shopping (visiting several different doctors to obtain a large volume of opioids without arousing 
suspicion).34 Currently every state has an operational PDMP or has enacted legislation for its 
provision.35 All state PDMPs collect data on the prescriptions filled by pharmacists, but beyond 
this shared central component, the functions and practices of state PDMPs vary greatly.35  For 
example, some states also collect information on prescriptions written by doctors, flag patients 
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who purchase opioids with cash, collect information on different schedules, and share data with 
neighboring states.35 All existing state PDMPs were created through legislation at the state level 
and most major differences in the overall structures of state PDMPs are outlined in these laws; 
however, regulation also plays an important role in PDMPs. The legislative acts which created 
the PDMPs designate their housing within different state agencies broadly categorized as 
Pharmacy Board/Licensing, Health and Human Services/Substance Abuse, or Law 
Enforcement.35 These agencies have some leeway to regulate PDMPs without having to pass 
new laws. For example, in 2014, Massachusetts updated its regulations to collect data on a 
broader range of drugs, mandate a greater frequency of reporting, and allow for automatic 
reporting to doctors.36 This regulatory authority, coupled with state-level implementation, gives 
states the ability to test potentially beneficial changes to PDMPs and the flexibility to adopt 
promising practices more quickly than they would be able to through legislative acts.  
 
Other interventions to prevent prescription opioid overdose include automatic alerts within 
electronic health records (EHR) to indicate that a patient exhibits signs of nonmedical opioid use, 
safe opioid disposal programs, drug testing prior to opioid prescribing, and increased availability 
of opioid overdose rescue drugs such as Naloxone.37 Substantial effort has also been expended 
creating formulations of opioids that have lower risk of addiction and are more difficult to 
abuse.38–41 Despite these multi-pronged efforts to combat prescription opioid overdose, mortality 
has remained stubbornly high. After a small decrease in prescription opioid mortality from 2011 
to 2012, deaths increased again every year from 2013 to 2016.3 In general, there is only weak 
evidence supporting many of these interventions. A recent systematic review of seven types of 
interventions (PDMPs, insurer restrictions on prescribing, state-level legislation, guidelines, 
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naloxone, safe disposal programs, and education programs) found only weak to moderate 
evidence in support of the evaluated interventions.42 In particular, the authors noted that no 
evaluations of state-level legislation and few evaluations of guidelines used comparison groups. 
Furthermore, little was done to differentiate between the effects of multiple interventions 
implemented simultaneously. Of the seven types of interventions evaluated, only provider and 
patient education programs had moderate evidence of an effect on patient outcomes, and these 
changes were generally only observed in the short-term. 
 
Morphine Equivalent Daily Dose Thresholds 
 
One commonly promoted component of programs to address the prescription opioid overdose 
epidemic is the establishment of MEDD thresholds. MEDD, also sometimes referred to as daily 
Milligrams Morphine Equivalent (MME), is a measurement that converts opioid prescriptions to 
their equivalent dose in morphine and divides the total prescription by days supply of the 
medication.43 This measurement allows for comparison among different types of opioid 
formulations and strengths. The values of these thresholds vary widely by the states and 
organizations that set them and are used in different ways to regulate prescribing practices. 
Organizations that use MEDD thresholds include state Medicaid agencies, health departments, 
PDMPs and medical boards, Medicare, private health insurers, EHR administrators, and the 
Veteran’s Administration (VA).44–46 Occupational health organizations such as the American 
College of Occupational and Environmental Medicine (ACOEM),47 the Official Disability 
Guidelines (ODG),48 and state workers compensation boards49–51 have also developed or adopted 
thresholds. Recently, the Centers for Disease Control (CDC) released their own MEDD threshold 
guidelines as part of a comprehensive strategy for combatting opioid use.52  
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Despite the proliferation of MEDD threshold policies in recent years, little work has been done 
to characterize or evaluate them. MEDD thresholds have been determined almost exclusively by 
expert opinion or adapted from other states and are generally not informed by clinical trials or 
observational studies. Evaluations of the effect of MEDD threshold policies have been limited to 
Washington State. Washington uses a different threshold than many other states and 
organizations and is not representative of populations elsewhere in the country, necessitating 
research into MEDD threshold policies in other contexts. Furthermore, evaluations in 
Washington State have not included a comparison state or examined the differential effect of the 
policy in relevant clinical subgroups, such as cancer patients or individuals with terminal 
illnesses. 
 
While setting MEDD thresholds may discourage high dose prescribing—an important risk factor 
for prescription opioid mortality—the use of MEDD thresholds is not without criticism. As a 
practical matter, while MEDD policies are generally intended to restrict total prescribed dose, 
prescribers may fail to take into account early prescription refills or opioid prescriptions from 
other sources when calculating the MEDD. Even when calculating MEDD for a single 
prescription, prescribers may still encounter issues. For example, in 2015, researchers sent a 
survey to pharmacists, physicians, nurse practitioners, and physicians assistants asking them to 
calculate the morphine equivalents for four different drugs using any resources available to 
them.53 For each drug and among each provider group, their calculations had enormous 
variability. While a small number of policies provide mechanisms to automatically calculate 
MEDD and take into account multiple and overlapping prescriptions (e.g., states with alert 
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systems/automatic reports), most policies leave it to the provider to make these calculations. 
There is also a larger critique of MEDD as a measure, namely that it downplays important 
differences between different opioid formulations, particularly fentanyl and methadone.53,54 
Critics also argue that it is impossible to assign a single MEDD threshold level to all opioid 
users, regardless of body mass, condition, or individual tolerance levels.53–55  
 
Objective, Specific Aims, and Hypotheses 
Given the lack of evidence supporting MEDD threshold policies, there is a clear need for 
rigorous evaluation of existing policies. The overall goal of this research is to characterize 
existing state-level MEDD threshold policies in the United States and to evaluate the impact of a 
selection of these policies on prescribing practices in workers’ compensation and privately 
insured populations. Specific aims of the research are as follows: 
Aim 1. Systematically review and document existing MEDD threshold policies at the national, 
state, and local levels.  The following product shall be created upon completion of this aim: 
Product 1. A compendium of state-level MEDD threshold policies implemented in the 
United States. For each policy, information will be compiled about threshold value, date of 
implementation, policy exclusions, and date of implementation.  
 
Aim 2. Determine the impact of state workers’ compensation board policies identified in Aim 1 
on prescribed dose using claims data from a large, national workers’ compensation insurer 2010-
2013. I hypothesize that: 
Hypothesis 2.1. There will be an overall decrease in prescribed opioid dose in states with 
workers’ compensation board MEDD threshold policies relative to states no such policies.  
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Hypothesis 2.2. Workers’ compensation board MEDD policies will be associated with a 
greater decrease in MEDD among opioid users with chronic, non-cancer pain—the group 
primarily targeted by the policies—than among users with acute pain or cancer diagnoses. 
Hypotheses 2.1 is consistent with the results of evaluations of MEDD threshold guidelines in 
Washington State.56 To date, no study has looked at the impact of MEDD threshold policies in 
cancer and acute pain patients separately to determine if policies are being targeted as intended. 
 
Aim 3. Determine the impact of state health department, medical board, PDMP, and legislative 
policies on prescribed opioid dose in a privately insured population. I hypothesize that: 
Hypothesis 3.1. There will be a reduction in prescribed opioid dose in states with MEDD 
threshold policies from pre- to post-implementation periods relative to states without such 
policies. 
Hypothesis 3.2. The passage of rules/regulations, legislative acts, and passive alert systems 
compared to the passage of guidelines, will be associated with larger decreases in MEDD 
prescribed opioid doses.  
Hypothesis 3.1 is consistent with prior evaluations of MEDD threshold guidelines in 
Washington State,56,57 in workers’ compensation and Medicaid populations, respectively. 
However, it is unknown whether guidelines would have the same impact in privately insured 
populations, where insurers may not be able to exercise as significant influence. Similarly, other 
types of MEDD threshold policies, including rules/regulations, legislative acts, and passive alert 
systems, have not been evaluated. However, evaluations of prescribing policies in other contexts 
support the hypothesis that other types of policies may be more effective than guidelines in 
changing prescriber behavior. These studies have generally found that adherence to published 
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prescribing guidelines is low, even years after a guideline has been published.58–61 However, 
passive alert systems—systems that notify providers of prescribing guidelines either through 
decision support within an EHR, by e-mail or through paper letters during or shortly after 
eligible patient encounters—tended to significantly improve provider adherence to prescribing 
guidelines, particularly when the alerts were timely and provided a recommended course of 
action.58–60,62,63 One study which systematically reviewed several types of policy structures found 
that multimodal methods had stronger effects than single methods.59  
 
Innovation 
To date, no systematic documentation of MEDD threshold policies within the United 
States has been published. Existing reviews are not comprehensive and leave out critical 
information necessary to evaluate the effect of these policies. This compendium is a necessary 
first step to evaluations of MEDD threshold policies and will be an invaluable tool to 
researchers. A review that comprehensively documents threshold levels, date of implementation, 
means of measurement and enforcement, and means of dissemination is needed to set pre- and 
post- periods, select appropriate comparison states, and differentiate between specific and non-
specific effects of the policies. Building off of the review of threshold levels, this project will 
then analyze the impact of a selection of state policies on prescriber behavior in workers’ 
compensation and privately insured populations. This will be the first analysis of MEDD 
threshold policies outside of Washington State and the first evaluation that utilizes comparison 
states, strengthening the case for a causal relationship. Since Washington implemented their 
MEDD guideline, several state and national organizations have implemented their own policies 
with varying threshold levels and methods of enforcement and dissemination. Evaluations of 
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these policies can provide insight into which strategies have the biggest impact on prescribing 
practices and patient outcomes. These results can then provide guidance to organizations who are 
considering adopting or revising MEDD threshold policies. 
 
Conceptual Framework 
The Donabedian Quality of Care Model64 is the guiding conceptual framework. The 
Donabedian model examines healthcare quality issues through a lens of structure, process, and 
outcome, with structures representing the resources, environment, and policies in place, process 
representing the actions of the medical establishment, and outcomes representing health 
outcomes experienced by patients. In this dissertation, Chapter 2 addresses structure, Chapters 3 
and 4 addresses process, and future research addresses outcomes. Chapter 2 will define the 
structure of MEDD threshold policies and describe the “policy environment” faced by 
prescribers who work within certain states or with different patient groups. Chapters 3 and 4 will 
evaluate the impact of MEDD threshold guidelines on prescribers’ processes of prescribing 
opioids in workers’ compensation and private insurance populations, respectively. The primary 
measures of interest in Chapters 3 and 4 will be average MEDD, which is a function of the 
strength of the opioids prescribed, the volume of pills prescribed, and number of simultaneous 
prescriptions. Future work will evaluate the impact of MEDD threshold policies on patient 
outcomes: time to RTW and opioid overdose or adverse events. This framework is presented in 
Figure 1 with the specific structures and processes addressed highlighted in red. The other 
structures, processes, and outcomes are outside the scope of this dissertation, but will be 
considered in the interpretation of results and addressed in future work. 
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Figure 1. Conceptual modela 
 
aAdapted from the Donabedian  Quality of Care Model
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Chapter 2. State-Level Morphine Equivalent Daily Dose Policies, 2007-2017 
 
Introduction 
Prescription opioid misuse is a significant problem which has gained considerable national 
attention in recent years. In particular, prescription opioid-related mortality has doubled in the 
United States between 2002 and 201665 prompting a flurry of recommendations and policies 
aimed at stemming the epidemic. While a robust literature exists detailing the epidemiology of 
prescription opioid misuse, there is a lack of consensus as to which policies are most effective at 
reducing mortality and improving patient outcomes.42 Previous research indicates that patients 
who receive higher doses of prescription opioids have an increased risk of overdose and 
mortality relative to patients who receive lower doses.66–68 Given this association, a commonly 
promoted tool to address the prescription opioid overdose epidemic is the establishment of 
Morphine Equivalent Daily Dose (MEDD) thresholds. MEDD, also sometimes referred to as 
daily Milligrams Morphine Equivalent (MME), is a measurement that converts opioid 
prescriptions to their equivalent dose in morphine and divides the total prescription by days 
supply (the number of days the prescription is intended to last).43 This measurement allows 
comparison among different types of opioid formulations and strengths, and accounts for 
multiple prescriptions patients may simultaneously receive. The threshold levels and structures 
of these policies vary widely by the states and organizations that set them, and are used in 
different ways to regulate prescribing practices. The first MEDD threshold policy was in the 
form of an interagency guideline passed by Washington State in 2007, which set a “yellow flag” 
threshold of 120 MEDD based on the recommendation of a consensus panel of prescribers.69 
Since that time, a majority of states have implemented some type of MEDD policy, though 
evaluations of the policies have been limited to Washington State.56,70,71 
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The purpose of this article is to comprehensively describe the landscape of MEDD threshold 
policies at the state level. Currently, no comprehensive list of these policies exists. In this article, 
MEDD threshold policies refer to state-level guidelines, legislative acts, rules and regulations, 
criteria for claim denial or prior authorization, or passive alert systems which seek to reduce the 
MEDD prescribed to patients. Specific features of these policies are described and documented 




A systematic search of state-level MEDD threshold policies enacted from January 1, 2007 to 
June 1, 2017 was conducted. LexisNexis and Westlaw Next were used to conduct a 
comprehensive search of legislative acts in all 50 states and the District of Columbia using the 
terms “morphine equivalent,” “milligrams morphine,” “opioid dose threshold,” and “opioid dose 
maximum.” These same terms were also used to find non-legislative state-level policy 
documentation on Google. Additionally, each state Medicaid Agency, Health Department, 
Prescription Drug Monitoring Program, Workers' Compensation Board/Division, Medical Board, 
and Pharmacy Board website was checked to determine if any other MEDD threshold policies 
existed. The comprehensiveness of the list was validated in several ways. First, the list was 
checked against existing compilations of policies such as the Agency for Healthcare Research 
and Quality (AHRQ) guideline clearinghouse,72 The Brandeis PDMP Center of Excellence’s 
report on PDMPs with passive alert systems,46 the National Alliance for Model State Drug Laws 
2016 report on State Pain Management and Prescribing Policies,73 and the University of 
Wisconsin Pain and Policy Studies Group’s 2015 Report on Profiles of State Policies Governing 
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Drug Control and Medical Pharmacy Practice.74 None of these compilations are comprehensive, 
cover the full range of policy types examined in this paper, or systematically code characteristics 
of the policies, but they do serve as useful checks on the completeness of the current study. The 
Medicaid policies were checked against the Medicaid Drug Utilization Review (DUR) Annual 
Report Survey,75 which lists states with Medicaid agencies responding “yes” to the question, 
“Have you set recommended maximum morphine equivalent daily dose measures?” Second, the 
list was checked against academic literature using the above search terms, for references to 
MEDD threshold policies. Finally, for states with no MEDD threshold policy found, at least one 
representative from a state health agency was contacted to confirm the lack of a formal policy. 
The positions of these representatives varied based on publicly available contact information, but 
frequently included the state’s PDMP administrator or a member of the state’s Medicaid DUR 
Board. In some cases, the representative could not confirm the lack of a policy, but was able to 
refer me to another individual with more knowledge of policies in the state. State and national 
opioid policies which involved MEDD but did not meet all of the study’s inclusion and exclusion 
criteria were collected and are listed in Appendix 1, but should not be considered comprehensive. 
 
After the final list of MEDD threshold policies was completed, documentation for each policy 
was reviewed to define a list of variables for coding each policy. A second researcher 
independently coded each policy according to this list of variables and refined code definitions 
where needed. The final list of variables included state, the effective date of the policy, 
organization(s) that contributed to the policy, policy type, threshold level, patient groups 
excluded from the policy, whether or not short courses of opioids were excluded from the policy, 
and under what circumstances the threshold level may be exceeded. Policy type definitions are 
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defined in Table 1. Two researchers independently coded the first eight policies (alphabetically 
by state) and had a divergence rate of 33%. Divergent codes were discussed and resolved and 
clarifying edits were then made to the codebook based on divergent answers. The two 
researchers then independently coded the remaining policies with a divergence rate of 21% and 
repeated the process of resolving differences in coding and clarifying the codebook based on 
divergent answers. Divergent codes occurred most frequently for the categories “patient groups 
excluded from the policy” and “under what circumstances the threshold level may be exceeded.” 
The full protocol and codebook are provided in Appendix 2. 
 
Results 
Between January 1, 2007 and June 1, 2017, 22 states (43% of all states) enacted 31 MEDD 
threshold policies (Table 2). The most common policy structure observed was guideline (13 
states) followed by prior authorization (4 states), rule/regulation (4 states), legislative act (3 
states), claim denial (2 states), and alert system/automatic patient report (2 states). A map of 
policy type by state is displayed in Figure 1. 
 
The state-level agencies or organizations responsible for the policies were most frequently the 
state’s medical board (9 states), workers’ compensation board/agency (5 states), health 
department (5 states), legislature (3 states), pharmacy board (2 states), and PDMP (2 states) with 
some state policies being implemented by multiple agencies or organizations.  
 
A majority of states explicitly excluded certain patient groups from their MEDD policies with 
the most common exceptions being for terminal/hospice/palliative care patients (12 states), 
 18  
acute/etiologic pain patients (10 states), and cancer/malignant pain patients (8 states)(Table 2). A 
majority of states also had policies which specified circumstances under which MEDD 
thresholds could be exceeded or triggered recommended or required actions when a threshold 
was exceeded. Most commonly, these circumstances involved referral to a specialist (14 states), 
pain contract/patient education (7 states), clinical judgment (6 states), or improved pain or 
function (5 states). Five states made exceptions for short courses of opioids, defined as less than 
90 days (4 states) or 4 days (1 state). 
 
The first policy was in the form of a guideline implemented in 2007 by Washington State which 
recommended against prescribing above 120 MEDD. This guideline has served as a model for 
other states with a plurality of states (10) adopting the 120 MEDD threshold (Table 2).  
 
Over the years, progressively lower thresholds have been introduced in state guidelines (Figure 
2). Other types of potentially higher impact policies have also been introduced in more recent 
years. While it is difficult to comment on trends given the small number of each of these types of 
policies, it is notable that the two claim denial policies have the highest thresholds (300 MEDD) 
and there appears to be an overall trend of higher dose thresholds among more restrictive policy 
types, such as Legislative Acts, Claim Denial, and Prior Authorization. In general, early policies 
had higher thresholds that were broadly applied. More recent policies have lower thresholds and 
stricter enforcement mechanisms, but are more specific about who the policy is intended to 
cover.  
 
 19  
A few states have enacted multiple policies (Figure 3). In some cases, states have moved from 
less restrictive to more restrictive policy types. For example, Colorado released a guideline in 
2014, then implemented prior authorization and claim denial in 2016. Other states have had 
multiple organizations implement guidelines or have lowered their thresholds. 
 
Discussion 
MEDD threshold policies have proliferated over the past decade, but there is significant variation 
in these policies. Overall, there has been a trend away from guidelines to more restrictive policy 
types as well as a decrease in threshold level. Most policies explicitly acknowledge that MEDD 
threshold levels should not apply to certain patient groups or allow for circumstances under 
which thresholds may be exceeded.  
 
It is important to note that the lack of a MEDD threshold policy should not be construed as a lax 
regulatory opioid environment for a state. Many types of prescription opioid policies exist and 
MEDD thresholds are only one way of influencing prescribing behavior. Some states with no 
MEDD threshold policy which meets this study’s criteria have other types of opioid policies 
including Medicaid lock-in programs for opioid users,76 formularies that require prior 
authorization for some or all types of opioids,77 quantity limits for individual types of opioids,78 
or limits on days supply of opioids.79 While none of these policies specifically sets a MEDD 
threshold, it is reasonable to expect that these types of policies may nonetheless lower the overall 
MEDD prescribed. 
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Conversely, it is also important to note that MEDD threshold policies may not always work as 
intended. While the MEDD policies included in this study are all intended to restrict total 
MEDD, prescribers may not take into account opioid prescriptions from other sources or early 
prescription refills when calculating the MEDD they are prescribing. On a more basic level, there 
is still a lack of understanding among providers on how MEDD is calculated. A 2015 study sent 
a survey to pharmacists, physicians, nurse practitioners, and physicians assistants asking them to 
calculate the morphine equivalents for four different drugs using any resources available to 
them.53 For each drug and among each provider group, their calculations had enormous 
variability. While a small number of policies provide mechanisms to automatically calculate 
MEDD and take into account multiple and overlapping prescriptions (e.g., the two states with 
alert systems/automatic reports), most policies leave it to the provider to make these calculations. 
 
Beyond the practical consideration of calculating MEDD, there is also a broader criticism of 
MEDD as a measure. Many researchers have argued that MEDD policies dangerously downplay 
important differences between different opioid formulations or fail to take into account 
individual differences in drug tolerance.53–55  
 
In February of 2016, the Centers for Disease Control (CDC) implemented their own MEDD 
threshold guideline which stated that prescribers “should carefully reassess evidence of 
individual benefits and risks when increasing dosage to ≥50 morphine milligram equivalents 
(MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision 
to titrate dosage to ≥90 MME/day.”80 The guideline was well publicized and one might expect 
that, following the passage of this guideline, there would be less variation in MEDD threshold 
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level for new policies. However, this change did not appear to have a significant effect on state-
level policies. Of the seven state-level policies enacted following the CDC guideline, threshold 
values varied widely (between 30 and 300), and only two of those states (Alaska and Wisconsin) 
set thresholds in line with CDC recommendations. The continued variation in policy may be due 
to the cautious language used by the CDC in endorsing a dose threshold or it may be that only 
states who did not agree with the CDC guidelines felt that it was necessary to implement their 
own policies. Further research on states’ processes for setting threshold levels is necessary to 
understand why such variation has persisted. 
 
In addition to processes by which states set thresholds, understanding a number of other policy 
characteristics not explored here may be of great interest and aid in the future evaluation of these 
policies. In particular, information about enforcement mechanisms was often lacking from the 
policy documentation. For example, Medical Board Rules are stated as imperatives, and, in 
theory, violating these rules may result in losing one’s medical license. However, it is unclear 
how frequently this happens in practice. It is not clear that these states have any automated way 
of verifying these rules are followed and noncompliance may only be discovered among audits 
of high volume prescribers. Conversely, guidelines, which do not use imperative language, may 
nonetheless make big impacts on prescribing behavior. Guidelines can be used by individual 
insurers within a state to justify claim denial of high dose prescriptions or target high dose 
prescribers for utilization review. Understanding the nuanced mechanisms by which MEDD 
threshold policies influence provider behavior would require in-depth qualitative research that is 
beyond the scope of this manuscript, but is an important area for future research. 
 
Public Health Implications 
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MEDD thresholds are a promising policy tool, but there is a lack of consensus as to how the 
thresholds should be used and what at what threshold level they should be set. Further research is 
needed to determine which types of policies are most effective and if they are targeting the 
patients most at-risk for overdose. Understanding the variation in MEDD threshold policies is an 
important first step in evaluation. 
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Tables 
Table 1. Policy type definitions 
Term Definition 
Guideline/recommendation  Provides a recommended threshold over which prescribers 
should not exceed or should only exceed if special 
precautions are taken. Guidelines/recommendations have no 
mechanism of enforcement. 
Rules/regulations  Similar to guidelines, but are stated as an imperative (e.g., 
“must” “shall”) and may or may not have an explicit means 
of enforcement.  
Legislative Act  Any law passed by the state’s legislative body which has 
gone into effect. Proposed bills that never became law are 
not included.  
Alert System/Automatic 
Patient Report  
A mechanism by which targeted, unsolicited letters or alerts 
sent either by mail or electronically and inform prescribers 
that patients under their care have exceeded a given MEDD 
threshold. Follow-up action may or may not be required. 
Prior Authorization  A requirement that mandates prior approval from a third 
party before prescriptions above a given MEDD threshold 
may be filled. 
Claim Denial  A mechanism by which a third party denies prescription fills 
above a given MEDD threshold. In cases where Prior 
Authorization documentation explicitly states that 
prescriptions above a given MEDD threshold will not be 
approved, Prior Authorization and Claim Denial may be 
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States, Number (%) 
N=22 
Policies, Number (%) 
N=31 
Type of Policy   
Guideline 13 (59%) 15 (48%) 
Rule/Regulation 4 (18%) 4 (13%) 
Prior Authorization 4 (18%) 4 (13%) 
Legislative Act 3 (14%) 4 (13%) 
Claim Denial 2 (9%) 2 (6%) 
Alert System/Automatic Patient Report 2 (9%) 2 (6%) 
Sponsoring Organization   
Medical Board 9 (41%) 9 (29%) 
Medicaid 6 (27%) 7 (23%) 
Workers’ Compensation 5 (23%) 6 (19%) 
Health Department 5 (23%) 5 (16%) 
State Legislature 3 (14%) 4 (13%) 
Pharmacy Board 2 (9%) 2 (6%) 
PDMP 2 (9%) 2 (6%) 
Threshold Level   
30 2 (9%) 2 (6%) 
50 1 (5%) 1 (3%) 
60 1 (5%) 1 (3%) 
80 3 (14%) 4 (13%) 
90 4 (18%) 4 (13%) 
100 5 (23%) 5 (16%) 
120 10 (45%) 11 (35%) 
300 2 (9%) 2 (6%) 
Patient exclusions   
Terminal/hospice/palliative care  12 (55%) 14 (45%) 
Acute/etiologic pain 10 (45%) 10 (32%) 
Cancer/malignant pain 8 (36%) 11 (35%) 
Long-term care facility/nursing home  5 (23%) 5 (16%) 
ER care patients 2 (9%) 2 (6%) 
Other patient groups 3 (14%) 3 (10%) 
No patient groups excluded 7 (32%) 7 (23%) 
Short courses of opioids excluded 5 (23%) 5 (16%) 
Excluded circumstances   
Specialist consulted 14 (64%) 15 (48%) 
Pain contract/patient education 7 (32%) 7 (23%) 
Clinical judgment 6 (27%) 7 (23%) 
Improved pain or function 5 (23%) 5 (16%) 
Evidence of tapering 4 (18%) 4 (13%) 
PDMP checked 4 (18%) 4 (18%) 
Drug testing 3 (14%) 3 (10%) 
Other circumstances specified 3 (14%) 3 (10%) 
No circumstances specified 9 (41%) 10 (32%) 
Abbreviations: ER, Emergency Room; PDMP, Prescription Drug Monitoring Program 
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Figures 





Figure 2. MEDD threshold level and type over time 
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Appendix 1. Relevant MEDD policies not meeting inclusion criteria 
Citation: Alaska Medicaid. Prior Authorization Requirements Extended-Release/Long-acting 
Opioid Analgesics (all strengths). April 17, 2015. 
http://dhss.alaska.gov/dhcs/Documents/pharmacy/pdfs/Extended-Release-Opioids-
PA_201504_APPROVED.pdf. Accessed November 30, 2017. 
 
Policy Description: Establishes prior authorization for some types of opioids at any dose and 
quantity limits for some opioids.  
 
Reason Not Included: MEDD criteria did not apply to all opioid drugs and there is no overall 
MEDD prior authorization criteria. 
 
Citation: Health Options Highmark Blue Cross Blue Shield Delaware. Prior Authorization 
Conditions for High Dose Narcotics and Long and Short Acting Narcotics. January 2017. 
https://highmarkhealthoptions.com/sites/default/files/Narcotics.pdf. Accessed November 30, 
2017. 
 
Policy Description: Establishes quantity limits for long and short acting opioids. 
 
Reason Not Included: MEDD threshold only applies to single Managed Care Organization in 
Delaware and is not a statewide Medicaid policy. 
 
Citation: Georgia Composite Medical Board. Notice of Intent to Amend and Adopt Rules. 
https://medicalboard.georgia.gov/sites/medicalboard.georgia.gov/files/related_files/site_page/Rul
e%20360-3-.06%20Pain%20Management.pdf. Accessed November 30, 2017. 
 
Policy Description: Doctors must follow-up with patients taking >30 MEDD at least every 3 
months. 
 
Reason Not Included: The policy only applies to Schedule II and III opioids and only 
recommends increased follow-up after exceeding a given MEDD with no other recommended 
course of action. 
 
Citation: Electronic-Florida Online Reporting of Controlled Substances. 2015-2016 Prescription 
Drug Monitoring Program Annual Report. December 1, 2015. 
http://www.floridahealth.gov/statistics-and-data/e-
forcse/_documents/2016PDMPAnnualReport.pdf. Accessed December 8, 2017. 
 
Policy Description: E-FORCSE (Florida’s PDMP) provides an overall MEDD calculation for 
providers when they login to the report. 
 
Reason Not Included: Although MEDD calculations for providers when they login to the report, 






Citation: Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic 
pain. Illinois Department of Healthcare and Family Services and UIC College of Pharmacy. 
2014. https://www.illinois.gov/hfs/SiteCollectionDocuments/3opioidprescribing.pdf  
 
Policy Description: The Illinois State Medicaid Agency reviewed and disseminated existing 
opioid prescribing guidelines including MEDD guidelines, but did not explicitly endorse any 
specific guideline.  
 
Reason Not Included: This is a systematic review of existing guidelines rather than an 
endorsement of any guideline by an included state agency. 
 
Citation: Board adds CDC guideline on opioid prescribing to list of resources for chronic pain 






Policy Description: A statement from the Iowa Board of Medicine which encourages physicians 
to consider the 2016 CDC opioid prescribing guidelines including MEDD thresholds. 
 
Reason Not Included: This was considered a dissemination of existing CDC guidelines rather 
than guidelines sponsored by an included state-level organization. 
 




Policy Description: Requires prior authorization for opioid prescriptions above 120 MEDD. 
 
Reason Not Included: Passport Health is one of Kentucky Medicaid’s HMOs, but the prior 
authorization requirement does not apply to all Medicaid patients. 
 
Reference: Memo on High Dose Limits. The Commonwealth of Massachusetts 
Executive Office of Health and Human Services Office of Medicaid. January 2016. 
http://www.mass.gov/eohhs/docs/masshealth/pharmacy/opioid-letter-high-dose-limits.pdf  
 
Policy Description: Medicaid requires prior authorization for high doses of individual drugs 
above a certain MEDD threshold, but the threshold is drug dependent and there is no overall 
MEDD threshold in place. 
 
Reference: Minnesota Revisor 5221.6110. Long-Term Treatment with Opioid Analgesic 
Medication. https://www.revisor.mn.gov/rules/?id=5221.6110  
Policy Description: In workers’ compensation patients, increased follow-up is recommended for 





Reason not Included: Does not meet the inclusion criteria “Policies which recommend increased 
follow-up after exceeding a given MEDD with no other recommended course of action were not 
included.” 
Reference: Provider Bulletin Express Scripts Physician Outreach Program-Morphine Equivalent 
Dose (MED). Montana State Fund. http://safemt.com/express-scripts-physician-outreach-
program-morphine-equivalent-dose-med/   
 
Policy Description: Providers with patients receiving opioids paid for by the Montana State 
Fund—Montana’s state-funded workers’ compensation insurer—will receive letters when 
individuals receive opioids in excess of 120 MEDD.  
 
Reason Not Included: The Montana State Fund is only one workers’ compensation insurer in 
Montana and injured workers not covered by the fund are not subject to these alerts. 
 
Reference: Drug Utilization Review (DUR) Board Meeting. February 13, 2014. Mississippi 
Division of Medicaid. https://medicaid.ms.gov/wp-
content/uploads/2014/04/DURMinutes021314.pdf 
 
Policy Description: The Mississippi Drug Utilization Review Board proposed sending letters to 
providers treating patients receiving above 120 mg MEDD for 90 days or longer. Follow-up with 
a representative of the DUR to determine if this policy went into effect found that a similar 
policy did go into effect in September 2016, but letters are not sent to all providers prescribing 
above 120 mg MEDD. Rather, there is a limit to the number of letters sent each month. 
 
Reason not included: Due to the limit of letters sent each month, the policy does not apply to all 
patients in the Medicaid population.  
 
Reference: Big Data Analytics Cuts Medicaid Opioid Abuse, Ups Patient Safety. October 6, 
2015. Health IT Analytics. https://healthitanalytics.com/news/big-data-analytics-cuts-medicaid-
opioid-abuse-ups-patient-safety 
 
Policy Description: Missouri has prior authorization requirements for quantity and days supply 
of certain opioid drugs. They also have begun to track some high dose prescribing. 
 
Reason not included: There is no policy that includes an overall MEDD threshold across drugs. 
 
Reference: North Dakota Department of Human Services Narcotics Authorization Algorithm. 
North Dakota Department of Human Services. 
http://www.hidesigns.com/assets/files/ndmedicaid/Criteria/2015/Visio-Narcotics.pdf 
 
Policy Description: North Dakota requires prior authorization for certain drugs above dose of 
150 MEDD, 200 MEDD, and 300 MEDD depending on the drug. 
 
Reason not included: Only a small number of opioid drugs have the MEDD requirement and 




Reference: Relates to prior authorization for opioids and Medicaid. Ohio HB 250. GA 131. 
(2015). 
 
Policy Description: Proposed Bill in Ohio to implement Medicaid Prior Authorization 
requirement for all opioid prescriptions >80 MEDD. 
 
Reason not included: The bill was introduced, but ultimately not passed. 
 
Reference: Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain. 
Pennsylvania Medical Society. 2014. 
 
Policy Description: Guidelines recommending against opioid prescribing above 100 MEDD 
without a specialist referral. 
 
Reason not included: The Pennsylvania Medical Society would not be considered to be any of 
the types of organizations included in the study’s inclusion criteria. 
 
Appendix 2. Study protocol 
 
I. Date of Protocol: November 11, 2017 
 
II. Scope: A comprehensive survey of state-level Morphine Equivalent Daily Dose 
(MEDD) threshold policies. A doctoral candidate at Johns Hopkins researched and 
built this dataset under a dissertation grant from the Agency for Healthcare Research 
and Quality (AHRQ). To be included, the policy must meet all of the below inclusion 
criteria. The policy formats and state agencies selected were determined through an 
iterative process in which state level MEDD policies were searched for online and in 
the academic literature, and the list of included formats and agencies were updated to 
include the most common and frequently cited types of policies.  
 
III. Primary Data Collection 
a. Project Dates: June 1, 2017-October 17, 2017. The doctoral candidate conducted 
preliminary background research for this project May 1, 2015 to May 31, 2016. 
b. Dates Covered in the Dataset: January 1, 2007- June 1, 2017. The published 
dataset only includes the most recent version of each state’s policies, thus the 
published project is a cross-sectional dataset of state-level MEDD threshold 
policies in effect on June 1, 2017. 
c. Data Collection Methods: The research team consisted of the doctoral candidate 
(Researcher 1) who conducted preliminary background research, compiled the 
policy set, and coded the policies, a second researcher from the doctoral 
candidate’s institution who independently coded the policies (Researcher 2), and 
Researcher 1’s academic advisor who supervised the project (Supervisor). 
d. Databases Used: Researcher 1 used LexisNexis and Westlaw Next to conduct a 
comprehensive search of legislative acts in all 50 states and the District of 




documentation and checked each state’s Medicaid Agency, Health Department, 
Prescription Drug Monitoring Program, Workers' Compensation Board/Division, 
Medical Board, and Pharmacy Board websites to determine if any other MEDD 
threshold policies existed.  
e. Search Terms: “Morphine equivalent,” “Milligrams morphine”, “Opioid dose 
threshold,” and “Opioid dose maximum.” 
f. Initial Returns and Additional Inclusion or Exclusion Criteria: 
i. Policies must be of one of the following formats: 
“Guideline/Recommendation,” “Legislative Act,” “Rule/Regulation,” 
“Prior Authorization,” “Claim Denial,” “Alert System/Automatic Patient 
Report” and have been implemented by one of the following state-level 
organizations: “Medicaid Agency,” “Health Department,” “Prescription 
Drug Monitoring Program,” “State Legislature,” “Workers’ Compensation 
Board/Division,” “Medical Board,” or “Pharmacy Board.” Policy formats 
and state-level organizations are defined later in this document. 
ii. Policies from any private company or non-profit organization or from any 
type of national organization were not included unless they were co-
sponsored by one of the above state-level organizations.  
iii. Policies that reference policies implemented by other organizations (for 
example, in the background section of a report), but do not endorse the 
policy were not included. 
iv. Policies that only limit the MEDD for certain drugs (e.g., non-preferred 
drugs only or short-acting drugs only) or do not limit cumulative MEDD 
were not included.  
v. Medicaid and Workers’ Compensation prior authorization policies that do 
not apply to all Medicaid or Workers’ Compensation insurers within the 
state were not included.  
vi. Policies which recommend increased follow-up after exceeding a given 
MEDD with no other recommended course of action were not included. 
vii. Policies involving MEDD that did not meet inclusion criteria were 
compiled in a separate appendix, not published here, but should not be 
considered comprehensive. 
IV. Coding 
a. Development of Coding Scheme: Researcher 1 began with a number of a priori 
policy questions developed during the preliminary background research stage. As 
Researcher 1 compiled policy documentation and coded the policies, additional 
questions were added or modified with input from Researcher 2 and the 
Supervisor.  
i. Dataset terminology: 
 “Morphine Equivalent Daily Dose Policies” (hereafter “policy” or 
“policies”) are policies which seek to limit overall opioid 





 “MEDD” is a measurement that converts opioid prescriptions to 
their equivalent dose in morphine and divides the total prescription 
by days supply (the number of days the prescription is intended to 
last). Policies may also refer to MEDD as Milligrams Morphine 
Equivalent (MME). 
b. Coding Rules: 
i. Policies were coded for each state and each state may have multiple 
policies. Where states have multiple policies, they are presented beginning 
with the most recent policy.  
ii. The text coded was limited to MEDD Policies as previously defined. 
Other policies that were cited or cross-referenced in the policies were not 
coded or included in the policy source text. 
iii. Below are explanations of individual coding questions and their respective 
responses. 
 
 For the field “effective date” 
 For guidelines, when the guideline was first published. For all 
other policy formats, when the policy first became effective. For 
policies where only month and year are given, the first of the 
month is used, by default. When a state has multiple policies, the 
most recent is used for the effective date. For individual policy 
dates, refer to the questions “On what date did the policy become 
effective?” 
 For the questions “What is the type of policy?” 
 “Guideline/recommendation” provides a recommended threshold 
over which prescribers should not exceed or should only exceed if 
special precautions are taken. Guidelines/recommendations have 
no mechanism of enforcement. 
 “Rules/regulations” are similar to guidelines, but are stated as an 
imperative (e.g., “must” “shall”) and may or may not have an 
explicit means of enforcement.  
 “Legislative Act” is any law passed by the state’s legislative body 
which has gone into effect. Proposed bills that never became law 
are not included. 
 “Prior Authorization” is a requirement that mandates prior 
approval from a third party before prescriptions above a given 
MEDD threshold may be filled. Legislation which establishes a 
prior authorization requirement was coded as “Prior 
Authorization” and caution noted. 
 “Alert System/Automatic Patient Report” is a mechanism by which 
targeted, unsolicited letters or alerts sent either by mail or 
electronically and inform prescribers that patients under their care 
have exceeded a given MEDD threshold. Follow-up action may or 




 “Claim Denial” is a mechanism by which a third party denies 
prescription fills above a given MEDD threshold. In cases where 
Prior Authorization documentation explicitly states that 
prescriptions above a given MEDD threshold will not be approved, 
Prior Authorization and Claim Denial may be coded as two distinct 
policies. 
 For the questions “Which organization(s) contributed to the policy?” 
 “Medicaid Agency” is a state-run organization primarily funded by 
the federal government which provides healthcare to qualifying 
low-income individuals.  
 “Health Department” is a state government agency which supports 
public health in the state. They are also often referred to as 
Departments of “Health and Social Services” or “Public Health.” 
 “Prescription Drug Monitoring Program” (PDMP) collect 
prescribing and/or dispensing data of controlled substances 
including opioids. They may also be referred to as “Prescription 
Monitoring Programs.” 
 “State Legislature” refers to a state’s lawmaking body. 
 “Workers’ Compensation Board/Division” is a state agency 
responsible for setting workers’ compensation rules and 
regulations for the states. In some states, they may also provide 
workers’ compensation insurance either exclusively or alongside 
private insurers. 
 “Medical Board” is a state government organization which is 
responsible for licensing medical professionals in the state. 
 “Pharmacy Board” is a state government organization which is 
responsible for licensing pharmacists in the state. 
 “Other” refers to any other organization that co-sponsored the 
policy. The names of these organizations are caution noted. 
 For the questions “What is the MEDD threshold level?” 
 “MEDD threshold level” refers to the number of cumulative 
milligrams of morphine equivalent each day that the policy uses in 
the ways described above. If a range of values was given, the 
highest value in the range was used and the range was caution 
noted.  
 Policies that have a baseline MEDD threshold for all opioids, and 
then lower (stricter) MEDD thresholds for certain types of opioids 
were coded according to the baseline threshold. Where different 
threshold levels were associated with different patient group 
exemptions or different circumstances under which a threshold 





 If two different thresholds were mentioned with no explicit 
differences in exemptions or circumstances under which the 
threshold should be exceeded, the lower of the two thresholds was 
selected. 
 For the questions “Which types of patients, if any, are exempt from the 
policy?” 
 “Types of patients” refers to any patient population for whom the 
policy does not apply. For prior authorization, this specifically 
refers to individuals who do not need to go through the prior 
authorization process, regardless of whether these individuals will 
ultimately receive approval for the prescription.  
 “Acute/etiologic pain patients” was coded if the policy states that it 
does not apply to acute pain, that it does not apply to pain with a 
clear etiology or cause, or that it applies only to chronic pain. 
 “Terminal/hospice/palliative care patients” was coded if the policy 
states that it does not apply to any of the following: pain from a 
terminal condition, or individuals receiving hospice, palliative, or 
end-of-life care.  
 “Cancer/malignant pain patients” was coded if the policy states 
that it does not apply to patients with either cancer pain or 
malignant pain. 
 “Long-term care facility/nursing home patients” are exempt if the 
policy states that it does not apply to patients residing in either 
long-term care facilities or nursing homes. 
 “Patients with recent opioid use” are exempt if the policy states 
that it specifically applies to opioid naïve patients or new opioid 
prescriptions. 
 For the questions “Are short courses of opioids excluded from the 
policy?” 
 “Short course” refers to opioid prescriptions that are below a given 
days supply and are intended for short-term use. 
 This question was coded “Yes” where the threshold policy did not 
apply to short courses of opioids. 
 For the questions “How are short courses defined in number of days 
supply?” 
 Days supply is the maximum number of days the prescription(s) 
are intended to last.  
 Where the course was defined in the policy in months, this was 
coded in number of days with 30 days to a month assumed (e.g., 3 
months = 90 days). 





 Unless caution noted, it was assumed that the MEDD threshold 
may be exceeded if any of the indicated circumstances apply. 
Where multiple circumstances must apply in order for the 
threshold to be exceeded (e.g., Patient must receive drug testing 
and have pain contract/patient education) this was caution noted. 
 “Specialist” refers to any specified (e.g., pain specialist, orthopedic 
specialist) or unspecified specialized physician. “Specialist 
consulted” means that a specialist must be consulted either prior to 
writing prescription(s) exceeding the MEDD threshold or that 
filling prescription(s) in excess of the MEDD threshold should 
trigger a specialist referral. Specialist referrals were coded when 
they were recommended or mandatory and documentation was or 
was not required. 
 “Physician qualifications” was coded where there were any 
recommended or required qualifications that a physician should 
receive in order to write prescriptions in excess of the MEDD 
threshold. 
 “Evidence of tapering” was coded where prescriptions in excess of 
the MEDD threshold may be written if the patient is receiving 
consecutively lower MEDD over time or the physician has put in 
place a plan to gradually lower the patients MEDD. This may be 
recommended or mandatory and documentation may or may not be 
required. 
 “Patient has improved pain or function” was coded where 
prescriptions in excess of the MEDD threshold may be exceeded 
provided that the patient is experiencing decreased pain or 
increased function at the higher doses. This may be recommended 
or mandatory and documentation may or may not be required. 
  “Clinical judgment” means that the MEDD threshold may be 
exceeded if the prescriber believes that there is a medical 
justification to do so. Documentation may or may not be required. 
 “Prescription Drug Monitoring Programs” (PDMP) collect 
prescribing and/or dispensing data of controlled substances 
including opioids. Physicians or other authorized users may use 
these programs to view a patient’s prescribing history and possibly 
detect doctor shopping. “PDMP is checked” means that the state’s 
PDMP should be checked either prior to writing prescription(s) 
exceeding the MEDD threshold or that filling prescription(s) in 
excess of the MEDD threshold should trigger checking the PDMP. 
Checking the PDMP may be recommended or mandatory and 
documentation may or may not be required. 
  “Pain contract/patient education” may refer to the required or 




regarding proper use of opioids, educating patients on the risks of 
opioid use, working with patients to set realistic expectations about 
pain relief and practice self-management techniques, or any other 
risk mitigation strategy or change in treatment plan. This may 
occur prior to or after prescribing above the MEDD threshold, may 
be recommended or mandatory, and documentation may or may 
not be required. 
 “Stable pain and function with non-escalating doses” means that 
the patient may exceed the MEDD threshold if they are not 
experiencing worse pain and function and if their MEDD has not 
increased. This criterion may be recommended or mandatory and 
documentation may or may not be required. 
 “Legitimacy of prescription verified” applies specifically to 
policies for pharmacists. In this case, the pharmacist should verify 
the prescription with the patient’s physician prior to dispensing the 
prescription if the MEDD exceeds a given threshold. This criterion 
may be recommended or mandatory and documentation may or 
may not be required. 
 “Drug testing” may refer to the required or recommended action of 
testing a patient for narcotics use. This may occur prior to or after 
prescribing above the MEDD threshold, may be recommended or 
mandatory, and documentation may or may not be required. 
 
V. Quality Control: 
 
a. Background Research 
The comprehensiveness of the list was verified in several ways: 
 The list was checked against existing compilations of policies including the AHRQ 
guideline clearinghouse, The Brandeis Prescription Drug Monitoring Program (PDMP) 
Center of Excellence’s 2016 report on PDMPs with unsolicited reporting, the National 
Alliance for Model State Drug Laws 2016 report on State Pain Management and 
Prescribing Policies, and the University of Wisconsin Pain and Policy Studies Group’s 
2015 Report on Profiles of State Policies Governing Drug Control and Medical Pharmacy 
Practice. 
 Medicaid policies were checked against Medicaid Drug Utilization Review Annual 
Report Surveys, which lists states with Medicaid agencies responding “yes” to the 
question, “Have you set recommended maximum morphine equivalent daily dose 
measures?” 
 The list was checked against academic literature using the above search terms, for 
references to MEDD threshold policies.  
 For states with no MEDD threshold policy found, at least one representative from a 






Policy questions were reviewed by the Supervisor and questions were edited for clarity. 
Researcher 2 suggested additional modifications to questions during a preliminary coding of the 
first three state’s policies. Modifications were agreed upon by the two coders. Researchers 1 and 
2 then redundantly coded 100% of the policies. Agreement rates were calculated and 
disagreements were arbitrated by the Supervisor. Research 1 and 2 independently coded the first 
eight policies (alphabetically by state) and had a divergence rate of 33%. Divergent codes were 
discussed and resolved and clarifying edits were then made to the codebook based on divergent 
answers. The two researchers then independently coded the remaining policies and had a 
divergence rate of 21% and repeated the process of resolving differences in coding and clarifying 
the codebook based on divergent answers. Divergence rates were calculated October 23, 2017. 
When answers to questions were ambiguous in a policy as noted by one or both coders, an 








Appendix 3. Codebook 
 
1. Does the state have at least one type of MEDD policy? (MEDDPolicy1, binary) 
1.1. What is the type of policy? (Type1, categorical, mutually exclusive; options: 
“Guideline,” “Legislative Act,” “Rule/Regulation,” “Prior Authorization,” “Claim 
Denial,” “Alert System/Automatic Patient Report”) 
1.2. On what date did the policy become effective? (Date1, date) 
1.3.Which organization(s) contributed to the policy? (Organization1, categorical, check all 
that apply; options: “Medicaid Agency,” “Health Department,” “Prescription Drug 
Monitoring Program,” “State Legislature,” “Workers' Compensation Board/Division,” 
“Medical Board,” “Pharmacy Board,” “Other”) 
1.4. What is the MEDD threshold level? (Threshold1, numerical) 
1.5. Which types of patients, if any, are exempt from the policy? (PatientsExempt1, 
categorical, check all that apply; options: “Cancer/malignant pain patients,” “Sickle 
cell anemia patients,” “Acute/etiologic pain patients,” “Inpatient care patients,” 
“Terminal/hospice/palliative care patients,” “HIV/AIDS patients,” “Long-term care 
facility/nursing home patients,” “Emergency room care patients,” “Intra-operative care 
patients,” “Patients with recent opioid use,” “None apply”) 
1.6. Are short courses of opioids excluded from the policy? (ShortCourse1, binary) 
1.6.1. How are short courses defined in number of days supply? (DaysSupply1, 
numerical) 
1.7. Under which circumstances, if any, may the MEDD threshold be exceeded? 
(CircumstancesExceeded1, categorical, check all that apply; options: “Specialist 
consulted,” “Physician qualifications,” “Evidence of tapering,” “Patient has improved 
pain or function,” “Clinical judgment,” “Prescription Drug Monitoring Program is 
checked,” “Pain contract/patient education,” “Stable pain and function with non-
escalating doses,” “Legitimacy of prescription verified,” “Drug testing,” “None apply”) 
2. Does the state have at least two types of MEDD policy? (binary) 
2.1. What is the type of policy? (categorical, mutually exclusive options: “Guideline,” 
“Legislative Act,” “Rule/Regulation,” “Prior Authorization,” “Claim Denial,” “Alert 
System/Automatic Patient Report”) 
2.2.On what date did the policy become effective? (date) 
2.3.Which organization(s) contributed to the policy? (categorical, check all that apply 
options: “Medicaid Agency,” “Health Department,” “Prescription Drug Monitoring 
Program,” “State Legislature,” “Workers' Compensation Board/Division,” “Medical 
Board,” “Pharmacy Board,” “Other”) 
2.4. What is the MEDD threshold level? (numerical) 
2.5. Which types of patients, if any, are exempt from the policy? (categorical, check all that 
apply; options: “Cancer/malignant pain patients,” “Sickle cell anemia patients,” 
“Acute/etiologic pain patients,” “Inpatient care patients,” “Terminal/hospice/palliative 
care patients,” “HIV/AIDS patients,” “Long-term care facility/nursing home patients,” 
“Emergency room care patients,” “Intra-operative care patients,” “Patients with recent 
opioid use,” “None apply”) 
2.6. Are short courses of opioids excluded from the policy? (binary) 




2.7. Under which circumstances, if any, may the MEDD threshold be exceeded? 
(categorical, check all that apply; options: “Specialist consulted,” “Physician 
qualifications,” “Evidence of tapering,” “Patient has improved pain or function,” 
“Clinical judgment,” “Prescription Drug Monitoring Program is checked,” “Pain 
contract/patient education,” “Stable pain and function with non-escalating doses,” 
“Legitimacy of prescription verified,” None apply”) 
3. Does the state have at least three types of MEDD policy? (binary) 
3.1. What is the type of policy? (categorical, mutually exclusive; options: “Guideline,” 
“Legislative Act,” “Rule/Regulation,” “Prior Authorization,” “Claim Denial,” “Alert 
System/Automatic Patient Report”) 
3.2.On what date did the policy become effective? (date) 
3.3.Which organization(s) contributed to the policy? (categorical, check all that apply; 
options: “Medicaid Agency,” “Health Department,” “Prescription Drug Monitoring 
Program,” “State Legislature,” “Workers' Compensation Board/Division,” “Medical 
Board,” “Pharmacy Board,” “Other”) 
3.4. What is the MEDD threshold level? (numerical) 
3.5. Which types of patients, if any, are exempt from the policy? (categorical, check all that 
apply; options: “Cancer/malignant pain patients,” “Sickle cell anemia patients,” 
“Acute/etiologic pain patients,” “Inpatient care patients,” “Terminal/hospice/palliative 
care patients,” “HIV/AIDS patients,” “Long-term care facility/nursing home patients,” 
“Emergency room care patients,” “Intra-operative care patients,” “Patients with recent 
opioid use,” “None apply”) 
3.6. Are short courses of opioids excluded from the policy? (binary) 
3.6.1. How are short courses defined in number of days supply? (numerical) 
3.7. Under which circumstances, if any, may the MEDD threshold be exceeded? 
(categorical, check all that apply; options: “Specialist consulted,” “Physician 
qualifications,” “Evidence of tapering,” “Patient has improved pain or function,” 
“Clinical judgment,” “Prescription Drug Monitoring Program is checked,” “Pain 
contract/patient education,” “Stable pain and function with non-escalating doses,” 








Chapter 3. The Impact of Morphine Equivalent Daily Dose Threshold Guidelines on 
Prescribed Dose in a Workers’ Compensation Population 
 
Introduction 
Prescription opioids are used to effectively treat pain following injury, but carry a high risk of 
addiction and may result in overdose and death when taken at high doses or combined with other 
drugs. Prescription opioid-related mortality has doubled in the United States between 2002 and 
2016.65 Non-medical opioid use and addiction are of particular concern among those receiving 
prescriptions through workers’ compensation insurance. Workers often initiate opioid use 
following occupational injury and complications of opioid use, such as the development of an 
opioid use disorder, may delay return to work, increase utilization of other medical resources, 
and result in other adverse outcomes for employees.30,31 Previous research has found opioid use 
to be very common among injured workers. In a study of US workers’ compensation claims 
2000-2010, around one-third of workers with a time-loss shoulder or back injury receiving 
opioids, and nearly half of those patients went on to become long-term opioid users (>3 months 
of continuous use).32 Furthermore, research suggests that opioid users receiving workers’ 
compensation insurance, across all injuries, are more likely to receive high doses and to become 
chronic users than are opioid users in the general population.33 
 
Previous research has also established that high-dose opioid prescribing is a major risk factor for 
opioid overdose.66–68 Given this association, a commonly promoted tool to address the 
prescription opioid overdose epidemic is the establishment of Morphine Equivalent Daily Dose 
(MEDD) threshold guidelines. A number of state-level agencies, insurers, and organizations have 




organizations including Washington, Massachusetts, Connecticut, New York, and California, 
which have all passed MEDD threshold guidelines. MEDD, is a measurement that converts 
opioid prescriptions to their equivalent dose in morphine and divides the total prescription by 
days supply (the number of days the prescription is intended to last),43 allowing comparison 
among different types of opioid formulations and strengths. MEDD threshold guidelines set an 
overall dose over which prescribing is not recommended.  
 
Despite the proliferation of these guidelines, evaluations of the impact of MEDD guidelines on 
prescribing practices have been limited to Washington State. Evaluations of Washington’s 
MEDD threshold guideline in the Medicaid population found a reduction in opioid use from pre- 
to post- guideline implementation with the greatest reductions occurring in the proportion of 
patients receiving over 120 MEDD, which was the threshold level set by the Washington 
guideline.57,71 The studies did not make use of comparison states, but did note that the reduction 
was seen at a time in which opioid prescribing was increasing in the United States, overall. 
However, in another study using Washington workers’ compensation claims data, no statistically 
significant reduction in opioid poisonings and adverse events was observed following the 
passage of MEDD threshold guidelines, although these events may have been under-reported.81 
The goal of the present study is to evaluate the impact of two states’ MEDD threshold guidelines 
(Massachusetts and Connecticut) on the MEDD of filled prescriptions paid for by workers’ 






To evaluate the impact of workers’ compensation MEDD threshold guidelines, administrative 
claims data, 2000-2013, from a large, national workers’ compensation insurer was used. These 
data have been used previously to evaluate occupational injury clinical practice guidelines.32,82–84 
The data includes National Drug Codes (NDC), drug quantities, dates of service, International 
Classification of Disease, Version 9 (ICD9) codes, state, age, sex, and employment status prior 




To be included in the study, patients must be age 16-64, have a lost-time injury after January 1, 
2000, and have had at least one valid, active opioid prescription between January 1, 2010 and 
December 31, 2013. Valid opioid prescriptions were defined as having non-missing units and 
days supply. Units with values of 0 or >1000 and days supply 0 or >180 were considered 
missing, consistent with prior studies.85 Duplicate values (based on NDC, units, and fill date) 
were deleted. Opioid prescriptions and morphine equivalent conversion factors were identified 
using a crosswalk file from the Centers for Disease Control. Patients must reside in a treatment 
state (Massachusetts and Connecticut) or control state (Illinois, Indiana, and Pennsylvania). 
Control states were selected on the basis of not implementing Prescription Drug Monitoring 
Programs (PDMPs) or passing any major prescription opioid legislation during the study period 
and having parallel monthly MEDD trends prior to guideline implementation. Treatment states 
were selected if they enacted a workers’ compensation MEDD policy, as defined in Chapter 2, 
during the study period. States with monopolistic workers’ compensation, meaning that the state 
runs their own workers’ compensation program for most workers, were not included as control 








The primary outcome for this study was MEDD calculated at the person-month level by 
multiplying quantity, dose, and conversion factor and dividing by days supply, taking into 
account multiple and overlapping prescriptions. SAS code and an example of the MEDD 
calculation are provided in the Appendix. As the distribution of MEDD is highly skewed right, 
the natural log of MEDD was also tested as an outcome. MEDD dichotomized as >120 or ≤120 





Policy variables were defined in two ways: First, as a simple pre- and post- indicator for whether 
or not the policy was in effect during the given month. Second, a months since policy 
implementation variable was developed to allow for gradual policy dissemination over time. 
Massachusetts’ guideline was implemented February 2012 and Connecticut’s was implemented 
July 2012. 
 
Individual Level Variables 
 
In addition to age, sex, and full-time employment status, a number of derived variables were 
included in the analysis. These include high baseline opioid use (defined as >90 MEDD and 
>120 MEDD in at least one month prior to February 2012, which was the first policy 




in MEDD), six body region Abbreviated Injury Scores (AIS) which were calculated from ICD9 
codes using ICDPIC for Stata14.6 Injury Severity Score (ISS), a summary measure that squares 
and adds the three highest AIS score, also calculated using ICDPIC, was also calculated for 
descriptive purposes. Because ICDPIC does not include ICD9 codes for burns, a separate burn 
indicator was created defined as ICD9 codes with the first three digits 940-949.86 Indicators for 
whether or not the patient received an acute pain diagnosis and whether or not the patient had a 
cancer diagnosis, as defined by Mack et al.85, were also created. 
 
Analyses 
Generalized linear mixed models were used with MEDD as the primary outcome and person-
month as the unit of analysis. All models included state fixed effects, a linear time trend, and 
clustering at the individual and state level which account for correlated outcomes within 
individuals and within states. All models included controls for age, sex, six body region AIS, 
burn indicator, and months since the first opioid prescription. Policy variables tested included 
both dichotomous and months in effect variables as described in the previous section. All time 
variables (months since first opioid prescription, months since policy implementation, and the 
monthly linear time trend) were tested for multicollinearity, defined as variance inflation factors 
(VIF) >10. Models were stratified by months with no active opioid prescription in the previous 
month (new prescription months) and months with an opioid prescription in the previous month 
(continuing prescription months) to determine if the policy had a differential effect in these two 
groups. Models were stratified by the presence of acute pain diagnosis and by the presence of a 
cancer diagnosis. The Massachusetts policy is specifically geared towards chronic pain and, 
while neither the Massachusetts nor the Connecticut policy explicitly excludes cancer patients, 




that these policies would have either or no effect or a smaller effect in acute pain and cancer 
patients than in those with chronic, non-cancer pain. Models were also stratified by high baseline 
opioid use with larger effects of the policy hypothesized in individuals with high baseline use. 
 
Results 
Population characteristics by treatment group (control states, treatment states pre-policy 
implementation, and treatment states post-policy implementation) are presented in Table 1. The 
majority of individuals across all groups were male and had at least one acute pain diagnosis. 
Significant differences existed between treatment groups with a higher percentage of males in 
the treatment states (83.0% post-policy and 76.5% pre-policy) as compared to the control states 
(74.3%) (p<0.001). Individuals in the control states were more likely to be employed full-time 
prior to injury (92.6% in control states, 88.9% in treatment states pre-policy, and 89.7% in 
treatment states post-policy, p<0.001) and have an acute pain diagnosis (95.2% in control states, 
94.0% in treatment states pre-policy, and 93.1% in treatment states post-policy, p<0.001). 
Individuals in treatment states were on average older (43.9 (SD 10.7) in control states, 44.1 (SD 
10.7) in treatment states pre-policy implementation and 47.0 (SD 9.2) in treatment states post-
policy implementation, p<0.001) and had higher Injury Severity Scores (ISS) (3.7 (SD 4.5) in 
control states, 4.1 (SD 5.5) in treatment states pre-policy and 4.6 (SD 5.9) in treatment states 
post-policy, p<0.001). A greater proportion of person-months involved high-dose opioid use in 
treatment states than in control states and the percentage of individuals with high-dose opioid use 
increased from the pre- to the post-period (15.9% with MEDD >120 in control states, 17.3% in 
treatment states pre-policy and 23.6% in treatment states post-policy, p<0.001) (Table 2). There 




treatment states (10.2% in control states, 8.6% in treatment states pre-policy and 3.6% in 
treatment states post-policy, p<0.001). 
 
Unadjusted MEDD by state and month are presented in Figure 1. Prior to the first MEDD 
guideline implementation in Massachusetts, the control and treatment states had roughly parallel 
trends in monthly MEDD use. Average MEDD increased relatively linearly each month with a 
higher baseline MEDD in Massachusetts than in Connecticut or the control states. Following the 
passage of the Massachusetts guideline, average MEDD continued to increase for a couple of 
months before leveling off and finally decreasing. In Connecticut, average MEDD use appears to 
increase at a slower rate than in the control states following the passage of the Connecticut 
guideline and begins to level off and decrease slightly in 2013. 
 
Regression results for the entire population using both dichotomous and months in effect policy 
definitions are presented in Table 3. After adjusting for covariates, policy implementation was 
associated with a 9.26 mg decrease in MEDD (95% CI: -13.96, -4.56) from the pre- to post- 
period, relative to control states. Decrease in MEDD also became more pronounced over time. 
Policy implementation was associated with a 1.87 mg decrease in MEDD for each month since 
the policy’s implementation (95% CI: -2.37, 1.37, p<0.001).  
 
Using the natural log of MEDD and dichotomous MEDD outcome variables did not change the 
direction or significance of the relationship (Appendix, Tables 1-3). Using a dichotomous policy 
definition and log MEDD, policy implementation was associated with an 11% decrease in 




Appendix Tables 4-13 and summarized in Figure 2. As hypothesized, the policy was associated 
with larger decreases in MEDD among individuals without an acute pain diagnosis as compared 
to with an acute pain diagnosis, among individuals without a cancer diagnosis as compared to 
with a cancer diagnosis, and among patients with high baseline opioid use as compared to 
patients with no high baseline opioid use. Continuing opioid prescriptions saw larger increases 
than did new opioid prescriptions. When examining state guidelines individually, both the 
guidelines in Massachusetts and Connecticut were associated with significant decreases in 
MEDD relative to control states. However, the magnitude of these decreases were larger in 
Massachusetts than in Connecticut. 
 
Discussion 
Overall, the passage of MEDD threshold guidelines was associated with a decrease in the MEDD 
of filled prescriptions relative to control states. The magnitude of this reduction was greater the 
more months the policy was in effect. Additionally, there was a larger decrease in MEDD among 
the groups that the policy was intended to target, namely patients with chronic, non-cancer pain 
and high baseline use. Importantly, no statistically significant change in MEDD was observed 
among cancer patients—alleviating a common concern that these types of policies may prevent 
individuals with cancer from receiving adequate pain treatment. While significant reductions 
were observed in both states that passed guidelines, larger decreases were observed in 
Massachusetts than in Connecticut. It is unclear why larger decreases were observed in 
Massachusetts. Notably, Massachusetts had a higher MEDD threshold than Connecticut. It is 
possible that dissemination efforts in Massachusetts were more robust and identifying 




important topic for future research. Understanding the relationship between threshold level and 
impact on prescriber behavior is also an important topic for future research. It is possible that 
setting the threshold level too high may prevent at-risk patients from being identified, while 
setting the threshold too low may discourage providers from complying. 
 
This study has a number of important strengths, namely a large sample size and a study design 
that utilizes pre- and post- data from both treatment and control states. The dataset also contained 
diagnosis codes which allowed controls for injury severity and stratification by clinically 
important groups. 
 
Notable limitations include a dynamic policy environment in which a number of efforts to curb 
opioid prescribing are present. While the study carefully selected control states that had not 
passed major opioid legislation, implemented PDMPs, or implemented other types of MEDD 
policies during the study period, there are still a number of other important considerations. 
Efforts to restrict opioid prescribing at the local level were not systematically captured and, if 
present, may have influenced results. It was also assumed that national-level policy efforts did 
not differentially influence prescribing by state, but this assumption may not be valid. As with 
most claims data research from a single insurer, it is important to note that opioids not paid for 
by the workers’ compensation insurer are not captured. Additionally, the results of this study 
may not be generalizable to the workers’ compensation population as a whole and future work 





High dose prescribing is an important risk factor for opioid-related mortality, but it is not the 
only one. A number of recent policies are increasingly emphasizing the importance of limiting 
days supply of new opioid prescriptions to prevent addiction and long-term use as well as the use 
of alternative non-opioid pain treatment and management.52 There is also some concern that 
restriction of opioid use among long-term opioid users may lead to increased use of heroin or 
other illicit drugs, though evidence on this is mixed.87–89 Future research should examine the 
impact of these guidelines on patient outcomes to determine if reduction of MEDD leads to 








Table 1. Population characteristics by treatment group, N=6,562 people (66,656 person-months) 

















State, N (%)     
  MA N/A 1412 (69.4%) 517 (74.1%) N/A 
  CT N/A 622 (30.6%) 181 (25.9%) N/A 
  IL 1990 (44.4%) N/A N/A N/A 
  IN 549 (12.3%) N/A N/A N/A 
  PA 1,943 (43.7%) N/A N/A N/A 
Male, N (%) 3,329 (74.3%) 1,555 (76.5%) 579 (83.0%) <0.001 
Full-time  4,148 (92.6%) 1,809 (88.9%) 626 (89.7%) <0.001 
Age, Mean (SD) 43.9 (10.7) 44.1 (10.7) 47.0 (9.2) <0.001 
Acute pain 
diagnosis, N (%) 
4,265 (95.2%) 1,912 (94.0%) 650 (93.1%) 0.03 
ISS, Mean (SD) 3.7 (4.5) 4.1 (5.5) 4.6 (5.9) <0.001 
aIndividuals in treatment states may be counted in pre-policy period, post-policy period, or both 
bChi-square test for categorical variables and one-way ANOVA for continuous variables 
Abbreviation: ISS, Injury Severity Score 
 
 
Table 2. AIG person-month characteristics by treatment group, N=66,656 person-months (6,562 
people) 




















MEDD, N (%) 
6,374 (15.9%) 3,371 (17.3%) 1,665 (23.6%) <0.001 
Months >90 
MEDD, N (%) 
7,860 (19.6%) 4,264 (21.9%) 2,040 (28.9%) <0.001 
% New rx months 4,102 (10.2%) 1,663 (8.6%) 252 (3.6%) <0.001 
a. Individuals in treatment states may be counted in pre-policy period, post-policy period, or both 





Table 3. Regression results, continuous MEDD outcome with dichotomous and months policy in effect definitions, all patients 
(N=66,656 person-months) 
 Dichotomous policy definition Months in effect policy definition 
Variable Estimate 95% CI p-value Estimate 95% CI p-value 
Policy variable -9.26 (-13.96, -4.56) <.001 -1.87 (-2.37, -1.37) <.001 
Head AIS 0.80 (-0.83, 2.42) 0.337 0.81 (-0.82, 2.44) 0.329 
Face AIS 2.68 (-1.80, 7.17) 0.241 2.58 (-1.90, 7.07) 0.259 
Chest AIS -3.49 (-5.53, -1.46) <.001 -3.53 (-5.57, -1.49) <.001 
Abdomen AIS 10.80 (9.03, 12.56) <.001 10.77 (9.00, 12.53) <.001 
Extremities AIS 0.51 (-0.65, 1.67) 0.386 0.49 (-0.67, 1.65) 0.411 
External AIS 13.69 (11.28, 16.10) <.001 13.58 (11.17, 15.99) <.001 
Burn indicator -30.66 (-44.29, -17.04 <.001 -30.52 (-44.13, -16.90 <.001 
Age -0.98 (-1.10, -0.87) <.001 -0.98 (-1.10, -0.86) <.001 
Male 17.56 (14.80, 20.32) <.001 17.58 (14.82, 20.34) <.001 
Months after Jan 2012 0.65 (0.54, 0.77) <.001 0.73 (0.62, 0.85) <.001 
Full-time employee 21.30 (17.21, 25.40) <.001 21.30 (17.20, 25.40) <.001 
CT (reference=PA) -13.00 (-17.04, -8.97) <.001 -12.95 (-16.92, -8.98) <.001 
IL (reference=PA) -20.27 (-23.27, -17.27 <.001 -20.26 (-23.25, -17.26 <.001 
IN (reference=PA) -23.32 (-29.33, -17.31 <.001 -23.06 (-29.07, -17.05 <.001 
MA (reference=PA) 6.16 (2.81, 9.51) <.001 7.55 (4.28, 10.81) <.001 
Months since first opioid rx 0.73 (0.68, 0.78) <.001 0.73 (0.68, 0.78) <.001 
















Appendix 1. SAS Code for sample MEDD calculation 
 
Variable definitions 
Enrolid: Unique patient identifier 
Svcdate: Date prescription filled 
Daysupp: Days supply of prescription 
Strength: Mg per one unit count 
Metqty: Number of units of drug 
Mmecon: Conversion factor to milligrams morphine equivalent 
 
data opioidrx; 
input enrolid $ svcdate daysupp strength metqty mmecon; 
datalines; 
100 10JAN2010 15 15 30 1 
100 20JAN2010 90 180 10 1 
100 21JAN2010 10 10 15 1.5 
100 05FEB2010 60 30 50 1 




  length key 8;  
  do dt = "01JAN2010"d to "31DEC2015"d;  
  month=month(dt); 
  year=year(dt); 
   key + 1;  
    output;  
  end;  










create table monthly_opioid_analysis as 
SELECT enrolid, month, year 
, COUNT(distinct cats(enrolid, dt)) as days_ttl, sum(MEDD_rx) as MEDD_ttl 
  FROM calendar c  
  JOIN opioidrx x  
    ON c.dt > x.svcdate 
   AND c.dt <= end_dt  
 GROUP BY enrolid, year, month; 
 quit; 
 
 data monthly_opioid_analysis; 















Quantity Strength Conversion Factor 
1 01/10/2010 15 15 30 1 
2 01/20/2010 90 180 10 1 
3 01/21/2010 10 10 15 1.5 
4 02/05/2010 60 30 50 1 
5 03/06/2010 1 5 10 7 
 
 In January, the patient has 22 active days of opioid prescription (15 days from Rx1, 12 
days from Rx2, 11 days from Rx3 with overlapping days). The patient has 15 days at 30 
mg morphine equivalent/day ((15 pills*30 mg/pill*1 mg morphine equivalents/mg)/15 
days) from Rx1, 12 days at 20 mg morphine equivalents/day ((180 pills*10 mg/pill*1 mg 
morphine equivalents/mg)/90 days) from Rx2, 11 days at 20.45 mg morphine 
equivalents/day ((10 pills*15 mg/pill*1.5 mg morphine equivalents/mg)/11 days). This 
results in a MEDD of 41.59 for the month of January ((15 days*30 mg morphine 
equivalents/day)+(12 days*20 mg morphine equivalents/day)+(11 days*20.45 mg 
morphine equivalents/day)/22 active days. 
 In February, the patient has 28 active days of opioid prescription (28 days from Rx2 and 
24 days from Rx4 with overlapping days). The patient has 28 days at 20 mg morphine 
equivalents a day ((180 pills*10 mg*1 mg morphine equivalent/mg)/90 days) from Rx2 
and 24 days at 25 mg morphine equivalents a day ((30 pills*50 mg*1 mg morphine 
equivalent/mg)/60 days) from Rx4. This results in a MEDD of 41.43 for the month of 
February ((28 days*20 mg morphine equivalents/day)+(24 days*25 mg morphine 
equivalents/day))/28 active days. 
 In March, the patient has 31 active days of opioid prescription (31 days from Rx2, 31 
days from Rx4, and 1 day from Rx5 with overlapping days). The patient has 20 days at 
20 mg morphine equivalents a day ((180 pills*10 mg*1 mg morphine equivalents/mg)/90 
days) from Rx2, 31 days at 25 mg morphine equivalents a day ((30 pills*50 mg*1 mg 
morphine equivalent/mg)/60 days) from Rx4, and 1 day at 350 mg morphine equivalents 
a day ((5 pills*10 mg* 7 mg morphine equivalents a day)/1 day). This results in a 
MEDD of 56.29 for the month of March ((31 days*20 mg morphine 
equivalent/day)+(31 days*25 mg morphine equivalent/day) )+(1 day*350 mg morphine 
equivalent/day))/31 active days. 
 In April, the patient has 19 active days of opioid prescription (19 days from Rx2 and 15 
days from Rx4 with overlapping days). The patient has 19 days at 20 MEDD (180 
pills*10 mg*1 mg morphine equilavent/mg)/90 days from Rx2 and 15 days at 25 mg 
morphine equivalents a day ((30 pills*50 mg*1 mg morphine equivalent/mg)/60 days) 





Table 1. Regression results, Log MEDD outcome, dichotomous policy variable, all patients 
(N=66,656 person-months) 
Variable Estimate 95% CI p-value 
Policy -0.12 (-0.15, -0.09) <.001 
Head AIS 0.04 (0.03, 0.05) <.001 
Face AIS 0.04 (0.01, 0.07) 0.011 
Chest AIS -0.06 (-0.07, -0.04) <.001 
Abdomen AIS 0.16 (0.14, 0.17) <.001 
Extremities AIS -0.00 (-0.01, 0.00) 0.317 
External AIS 0.12 (0.10, 0.13) <.001 
Burn indicator -0.19 (-0.28, -0.09) <.001 
Age -0.01 (-0.01, -0.00) <.001 
Male 0.19 (0.17, 0.21) <.001 
Months after Jan 2012 0.01 (0.01, 0.01) <.001 
Full-time employee 0.19 (0.16, 0.22) <.001 
CT (reference=PA) -0.09 (-0.12, -0.07) <.001 
IL (reference=PA) -0.10 (-0.13, -0.08) <.001 
IN (reference=PA) -0.12 (-0.17, -0.08) <.001 
MA (reference=PA) 0.11 (0.08, 0.13) <.001 
Months since first opioid rx 0.00 (0.00, 0.01) <.001 
 
Table 2. Regression results, MEDD >120 outcome, dichotomous policy variable, all patients 
(N=66,656 person-months) 
Variable Estimate 95% CI p-value 
Policy -0.26 (-0.33, -0.18) <.001 
Head AIS 0.11 (0.09, 0.14) <.001 
Face AIS 0.24 (0.18, 0.31) <.001 
Chest AIS -0.15 (-0.19, -0.12) <.001 
Abdomen AIS 0.31 (0.29, 0.34) <.001 
Extremities AIS 0.06 (0.03, 0.08) <.001 
External AIS 0.14 (0.10, 0.19) <.001 
Burn indicator -0.57 (-0.88, -0.26) <.001 
Age -0.02 (-0.02, -0.01) <.001 
Male 0.46 (0.40, 0.52) <.001 
Months after Jan 2012 0.02 (0.02, 0.02) <.001 
Full-time employee 0.39 (0.30, 0.48) <.001 
CT (reference=PA) -0.09 (-0.16, -0.02) 0.008 
IL (reference=PA) -0.44 (-0.49, -0.38) <.001 
IN (reference=PA) -0.48 (-0.62, -0.34) <.001 
MA (reference=PA) 0.05 (-0.00, 0.11) 0.059 





Table 3. Regression results, MEDD >90 outcome, dichotomous policy variable, all patients 
(N=66,656 person-months) 
Variable Estimate 95% CI p-value 
Policy -0.27 (-0.34, -0.20) <.001 
Head AIS 0.12 (0.09, 0.14) <.001 
Face AIS 0.17 (0.10, 0.23) <.001 
Chest AIS -0.16 (-0.19, -0.13) <.001 
Abdomen AIS 0.30 (0.28, 0.33) <.001 
Extremities AIS 0.04 (0.02, 0.06) <.001 
External AIS 0.17 (0.13, 0.21) <.001 
Burn indicator -0.21 (-0.44, 0.02) 0.069 
Age -0.02 (-0.02, -0.01) <.001 
Male 0.38 (0.33, 0.44) <.001 
Months after Jan 2012 0.02 (0.02, 0.02) <.001 
Full-time employee 0.43 (0.35, 0.52) <.001 
CT (reference=PA) -0.05 (-0.12, 0.01) 0.111 
IL (reference=PA) -0.43 (-0.49, -0.38) <.001 
IN (reference=PA) -0.45 (-0.58, -0.32) <.001 
MA (reference=PA) 0.11 (0.06, 0.16) <.001 
Months since first opioid rx 0.01 (0.01, 0.01) <.001 
 
Table 4. Regression results, continuous MEDD outcome, months policy in effect, continuing 
prescription months (N=60,639 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -1.73 (-2.26, -1.19) <.001 
Head AIS 0.60 (-1.15, 2.36) 0.502 
Face AIS 2.68 (-2.16, 7.53) 0.278 
Chest AIS -3.92 (-6.11, -1.72) <.001 
Abdomen AIS 10.12 (8.22, 12.02) <.001 
Extremities AIS 0.45 (-0.81, 1.72) 0.483 
External AIS 13.20 (10.54, 15.85) <.001 
Burn indicator -33.73 (-48.98, -18.49 <.001 
Age -1.19 (-1.32, -1.06) <.001 
Male 18.40 (15.36, 21.43) <.001 
Months after Jan 2012 0.60 (0.48, 0.73) <.001 
Full-time employee 22.79 (18.31, 27.27) <.001 
CT (reference=PA) -14.78 (-19.11, -10.45 <.001 
IL (reference=PA) -23.06 (-26.34, -19.77 <.001 
IN (reference=PA) -24.22 (-31.11, -17.33 <.001 
MA (reference=PA) 6.22 (2.65, 9.79) <.001 







Table 5. Regression results, continuous MEDD outcome, months policy in effect, new 
prescription months (N=6,017 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -1.10 (-1.75, -0.45) <.001 
Head AIS 1.03 (-0.47, 2.52) 0.180 
Face AIS -0.31 (-4.38, 3.77) 0.883 
Chest AIS 1.15 (-0.81, 3.12) 0.249 
Abdomen AIS 3.93 (2.18, 5.68) <.001 
Extremities AIS 0.81 (-0.17, 1.80) 0.105 
External AIS 2.36 (0.52, 4.19) 0.012 
Burn indicator 3.89 (-5.20, 12.98) 0.402 
Age 0.05 (-0.04, 0.13) 0.273 
Male 2.71 (0.64, 4.79) 0.010 
Months after Jan 2012 0.50 (0.39, 0.61) <.001 
Full-time employee 4.36 (1.09, 7.63) 0.009 
CT (reference=PA) -0.47 (-3.74, 2.79) 0.776 
IL (reference=PA) 0.71 (-1.62, 3.04) 0.551 
IN (reference=PA) -0.69 (-4.25, 2.88) 0.705 
MA (reference=PA) 6.77 (4.14, 9.40) <.001 
Months since first opioid rx 0.02 (-0.04, 0.08) 0.556 
Table 6. Regression results, continuous MEDD outcome, months policy in effect, patients with 
cancer diagnosis (N=2,484 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect 1.17 (-1.24, 3.58) 0.340 
Head AIS 16.49 (8.67, 24.30) <.001 
Face AIS 26.23 (8.20, 44.27) 0.004 
Chest AIS -31.24 (-38.68, -23.79 <.001 
Abdomen AIS 16.10 (9.35, 22.85) <.001 
Extremities AIS -11.47 (-16.71, -6.23) <.001 
External AIS 18.17 (5.90, 30.43) 0.004 
Burn indicator 22.08 (-14.68, 58.84) 0.239 
Age 0.54 (-0.03, 1.11) 0.062 
Male 84.54 (70.20, 98.89) <.001 
Months after Jan 2012 -0.39 (-0.92, 0.13) 0.144 
Full-time employee 53.23 (33.66, 72.80) <.001 
CT (reference=PA) 22.57 (4.21, 40.92) 0.016 
IL (reference=PA) -61.44 (-75.55, -47.34 <.001 
IN (reference=PA) -4.48 (-33.92, 24.96) 0.766 
MA (reference=PA) 6.31 (-8.48, 21.09) 0.403 





Table 7. Regression results, continuous MEDD outcome, months policy in effect, patients with 
no cancer diagnosis (N=64,172 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -1.96 (-2.47, -1.45) <.001 
Head AIS -0.32 (-1.99, 1.34) 0.704 
Face AIS -0.54 (-5.20, 4.11) 0.819 
Chest AIS -2.54 (-4.68, -0.41) 0.019 
Abdomen AIS 10.46 (8.63, 12.30) <.001 
Extremities AIS 0.60 (-0.59, 1.80) 0.322 
External AIS 13.87 (11.41, 16.33) <.001 
Burn indicator -38.12 (-52.99, -23.25 <.001 
Age -1.04 (-1.16, -0.92) <.001 
Male 15.71 (12.90, 18.52) <.001 
Months after Jan 2012 0.78 (0.67, 0.90) <.001 
Full-time employee 20.14 (15.95, 24.33) <.001 
CT (reference=PA) -13.94 (-18.01, -9.87) <.001 
IL (reference=PA) -18.53 (-21.59, -15.46 <.001 
IN (reference=PA) -22.79 (-28.91, -16.66 <.001 
MA (reference=PA) 8.07 (4.73, 11.41) <.001 
Months since first opioid rx 0.74 (0.68, 0.79) <.001 
Table 8. Regression results, continuous MEDD outcome, months policy in effect, patients with 
acute pain diagnosis (N=63,394 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -1.69 (-2.22, -1.17) <.001 
Head AIS 1.08 (-0.57, 2.73) 0.199 
Face AIS 2.84 (-1.70, 7.38) 0.220 
Chest AIS -3.67 (-5.73, -1.61) <.001 
Abdomen AIS 11.28 (9.47, 13.09) <.001 
Extremities AIS 1.24 (0.02, 2.46) 0.046 
External AIS 15.68 (13.11, 18.26) <.001 
Burn indicator -30.61 (-44.40, -16.83 <.001 
Age -1.02 (-1.14, -0.89) <.001 
Male 19.57 (16.71, 22.42) <.001 
Months after Jan 2012 0.68 (0.56, 0.80) <.001 
Full-time employee 20.17 (15.93, 24.40) <.001 
CT (reference=PA) -11.11 (-15.20, -7.02) <.001 
IL (reference=PA) -19.77 (-22.86, -16.67 <.001 
IN (reference=PA) -21.84 (-28.03, -15.65 <.001 
MA (reference=PA) 9.23 (5.85, 12.61) <.001 





Table 9. Regression results, continuous MEDD outcome, months policy in effect, patients with 
no acute pain diagnosis (N=3,262 person-months) 
Variable Estimate 995% CI p-value 
Months Policy in Effect -3.84 (-5.12, -2.56) <.001 
Age -0.69 (-1.08, -0.29) <.001 
Male -24.74 (-33.70, -15.78 <.001 
Months after Jan 2012 1.65 (1.28, 2.02) <.001 
Full-time employee 40.22 (26.57, 53.88) <.001 
CT (reference=PA) -85.44 (-100.44, -70.4 <.001 
IL (reference=PA) -55.68 (-66.46, -44.91 <.001 
IN (reference=PA) -87.70 (-109.86, -65.5 <.001 
MA (reference=PA) -42.40 (-53.36, -31.43 <.001 
Months since first opioid rx 0.03 (-0.10, 0.17) 0.635 
Table 10. Regression results, continuous MEDD outcome, months policy in effect, patients with 
no high baseline use (>120 MEDD) (N=9,629 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -0.66 (-1.05, -0.26) 0.001 
Head AIS 0.12 (-1.12, 1.36) 0.850 
Face AIS -7.41 (-11.04, -3.79) <.001 
Chest AIS -2.49 (-4.09, -0.90) 0.002 
Abdomen AIS 3.84 (2.36, 5.32) <.001 
Extremities AIS -1.82 (-2.74, -0.90) <.001 
External AIS -7.86 (-9.80, -5.92) <.001 
Burn indicator -3.14 (-21.73, 15.45) 0.741 
Age -0.17 (-0.27, -0.08) <.001 
Male 7.44 (5.21, 9.67) <.001 
Months after Jan 2012 1.29 (1.04, 1.54) <.001 
Full-time employee 5.18 (1.99, 8.37) 0.001 
CT (reference=PA) -14.57 (-17.95, -11.18 <.001 
IL (reference=PA) -13.22 (-15.64, -10.80 <.001 
IN (reference=PA) -1.36 (-7.45, 4.74) 0.663 
MA (reference=PA) -4.93 (-8.90, -0.96) 0.015 






Table 11. Regression results, continuous MEDD outcome, months policy in effect, patients with 
high baseline use (>120 MEDD) (N=5,767 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -3.27 (-5.62, -0.93) 0.006 
Head AIS -13.56 (-20.53, -6.58) <.001 
Face AIS 8.99 (-11.58, 29.56) 0.392 
Chest AIS 4.81 (-4.74, 14.36) 0.323 
Abdomen AIS -18.28 (-25.75, -10.81 <.001 
Extremities AIS 0.24 (-5.25, 5.74) 0.931 
External AIS 24.17 (11.59, 36.75) <.001 
Burn indicator -152.65 (-214.59, -90.7 <.001 
Age -2.75 (-3.38, -2.13) <.001 
Male 19.88 (5.05, 34.71) 0.009 
Months after Jan 2012 -2.07 (-3.63, -0.51) 0.009 
Full-time employee 64.58 (40.92, 88.25) <.001 
CT (reference=PA) -49.84 (-70.65, -29.04 <.001 
IL (reference=PA) -79.12 (-94.55, -63.69 <.001 
IN (reference=PA) -97.40 (-133.02, -61.7 <.001 
MA (reference=PA) -6.59 (-30.86, 17.69) 0.595 
Months since first opioid rx 1.27 (1.07, 1.47) <.001 
Table 12. Regression results, continuous MEDD outcome, months policy in effect, 
Massachusetts and control states (N=58,966 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -1.93 (-2.47, -1.39) <.001 
Head AIS 2.10 (0.32, 3.87) 0.020 
Face AIS -5.11 (-10.06, -0.17) 0.043 
Chest AIS -3.61 (-5.85, -1.37) 0.002 
Abdomen AIS 11.69 (9.73, 13.65) <.001 
Extremities AIS -0.45 (-1.70, 0.81) 0.486 
External AIS 14.40 (11.76, 17.03) <.001 
Burn indicator -32.09 (-46.32, -17.86 <.001 
Age -1.13 (-1.26, -1.00) <.001 
Male 17.85 (14.80, 20.89) <.001 
Months after Jan 2012 0.73 (0.60, 0.85) <.001 
Full-time employee 18.84 (14.37, 23.31) <.001 
IL (reference=PA) -20.06 (-23.14, -16.97 <.001 
IN (reference=PA) -22.77 (-28.95, -16.59 <.001 
MA (reference=PA) 7.60 (4.21, 10.98) <.001 





Table 13. Regression results, continuous MEDD outcome, months policy in effect, Connecticut 
and control states (N=47,839 person-months) 
Variable Estimate 95% CI p-value 
Months Policy in Effect -1.60 (-2.60, -0.60) 0.002 
Head AIS 2.39 (0.82, 3.96) 0.003 
Face AIS 6.24 (2.02, 10.47) 0.004 
Chest AIS -7.78 (-9.71, -5.86) <.001 
Abdomen AIS 16.42 (14.77, 18.07) <.001 
Extremities AIS 2.46 (1.38, 3.54) <.001 
External AIS -0.69 (-2.94, 1.57) 0.551 
Burn indicator -12.28 (-24.45, -0.12) 0.048 
Age -0.37 (-0.48, -0.26) <.001 
Male 10.47 (8.01, 12.93) <.001 
Months after Jan 2012 0.84 (0.74, 0.93) <.001 
Full-time employee 14.34 (10.22, 18.45) <.001 
CT (reference=PA) -14.90 (-18.15, -11.64 <.001 
IL (reference=PA) -19.96 (-22.32, -17.61 <.001 
IN (reference=PA) -23.85 (-28.56, -19.14 <.001 







Chapter 4. The Impact of Morphine Equivalent Daily Dose Threshold Policies on 
Prescribed Dose in a Privately Insured Population 
Introduction 
Prescription opioids are an effective means of treating pain, but are frequently misused and may 
result in overdose and death when taken at high doses or combined with other drugs. Prescription 
opioid-related mortality has doubled in the United States between 2002 and 201665 and previous 
research has established that high-dose opioid prescribing is a major risk factor for opioid 
overdose.66–68 Given this association, a commonly promoted tool to address the prescription 
opioid overdose epidemic is the establishment of Morphine Equivalent Daily Dose (MEDD) 
threshold policies. MEDD, is a measurement that converts opioid prescriptions to their 
equivalent dose in morphine and divides the total prescription by days supply, the number of 
days the prescription is intended to last,43 allowing comparison among different opioid 
formulations and strengths. MEDD threshold policies set an overall dose over which prescribing 
is discouraged in some way, though the threshold level and type of policy varies widely by the 
states and organizations that promote them. These types of policies are typically not 
implemented in isolation, but rather as part of a comprehensive strategy on opioid prescription 
reform. From January 1, 2007 to June 1, 2016, 31 MEDD policies have been enacted by 22 states 
(Chapter 2). 
 
Despite the proliferation of MEDD policies, evaluations of their impact have been limited. 
Evaluations of Washington’s MEDD threshold guideline in the Medicaid population found a 
reduction in opioid use from pre- to post- guideline implementation with the greatest reductions 





guideline).57,71 The studies did not make use of comparison states, but did note that the reduction 
was seen at a time in which opioid prescribing was increasing in the United States, overall. 
Chapter 3 examined the impact of prescribed MEDD dose following the passage of workers’ 
compensation MEDD threshold guidelines in Connecticut and Massachusetts and found an 11% 
reduction in mg MEDD of filled opioid prescriptions following guideline passage relative to 
control states. To date, no studies of MEDD threshold policies have been conducted in the 
private insurance population and it is unknown whether policies targeted at the general 
population will have the same effects as those targeted at specific populations, such as Medicaid 
or Workers’ Compensation claimants, where payers may have more of an influence on 
prescribing practices. Furthermore, the impact of MEDD policies other than guidelines on 
prescribed dose have not been studied, though research in other contexts suggests that they may 
be more impactful than guidelines. For example, studies have generally found that adherence to 
published prescribing guidelines is low, even years after a guideline has been published,58–61 but, 
passive alert systems—systems that provide notifications to prescribers through EHR decision 
support, e-mail, or mailed letters—tended to significantly improve provider adherence to 
prescribing guidelines.58–60,62,63 The goal of the present study is to evaluate the impact of nine 
states’ MEDD threshold policies on the MEDD of filled prescriptions among individuals with 
private insurance. These policies include guidelines, rules/regulations/legislative acts, and 










Truven MarketScan© data was used to evaluate state-level policies implemented between 
January 1, 2010 and December 31, 2015. This dataset consists of commercial claims, both 
inpatient and outpatient, from 350 private payers. The data contains International Classification 
of Disease, Version 9 (ICD9) codes, discharge codes, facility codes, National Drug Codes 
(NDC), quantity of drug, days supply of drug, age, sex, and state of enrollee residence. 
MarketScan® commercial claims data has been previously used to conduct research on opioid 
utilization90 and the data are weighted by Truven Health to be representative of individuals in the 




To determine whether passage of policies was associated with change in the odds of receiving 
any opioids, analyses were conducted on a random sample of one million enrollees under the age 
of 65 from a treatment or control state (Figure 1). Individuals 65 and older were excluded, as 
these individuals may also have Medicare claims for opioid prescriptions, which are not 
observable in the data. 
 
Additional analyses were conducted on the entire population of enrollees under the age of 65 
from a treatment or control state with at least one valid, active opioid prescription between 
January 1, 2010 and December 31, 2015. Control states were selected on the basis of not 
implementing Prescription Drug Monitoring Programs (PDMPs) or passing any major 
prescription opioid legislation during the study period and parallel trends in MEDD prior to 










All outcomes were related to receipt or MEDD of valid, filled opioid prescriptions. Both receipt 
of any opioids and dose of opioids among those who received opioids were tested as outcomes to 
distinguish between potential effects of the MEDD threshold levels specifically and other co-
occurring policy features. 
 
Valid opioid prescriptions were defined as having non-missing quantities and days supply. 
Quantities with values of 0 or >1000 and days supply 0 or >180 were considered missing, 
consistent with prior studies.85 Due to discrepancies in the reporting of drug quantities, some 
quantities were misreported by a factor of ten and a cleaning protocol was implemented wherein 
certain values were modified. For example, the common quantity of 30 pills was often 
misreported as 300. This cleaning protocol is described in detail in Appendix 1. Duplicate values 
(based on NDC, units, and fill date) were deleted. Opioid prescriptions and morphine equivalent 
conversion factors were identified using a crosswalk file from the Centers for Disease Control.92 
Among the sample of one million enrollees, three outcomes were tested: Indicators for whether 
or not an enrollee had any opioid use, opioid use >60 MEDD, and opioid use >120 MEDD 
during a month in which the individual was enrolled. MEDD was calculated at the person-month 
level by multiplying quantity, dose, and conversion factor and dividing by days supply, taking 
into account multiple and overlapping prescriptions. SAS code and an example of the MEDD 
calculation is provided in Appendix 1-2 of Chapter 2.  
 
Among the population of enrollees with any opioid use, the primary outcome of interest was 





MEDD was also tested as an outcome. MEDD dichotomized at the 120, 100, 80, and 60 MEDD 
threshold levels were also tested, corresponding to the thresholds used by the policies of the nine 





The policies examined in this study have been described in detail in Chapter 2. Briefly, policy 
types include guidelines, rules/regulations, legislative acts, and passive alert systems, with 
guidelines theorized to be less impactful than other types of policies. The policy types, threshold 
levels, and populations specifically excluded from the policy are detailed in Table 1. Policy 
variables were defined in two ways: First, as a simple pre- and post- indicator for whether or not 
the policy was in effect at the time. Second, a months since policy implementation variable was 
developed to allow for gradual policy dissemination over time. The timeline for policy 
implementation is shown in Figure 1. Policy variables were also defined as “any policy” and 
stratified by whether the policy was a “guideline” or a “strong policy” based on their theorized 
impact. Strong policies included rules/regulations, legislative acts, and passive alert systems. 
With the exception of two states, states only implemented one type of policy. Arizona 
implemented a strong policy prior to implementing a guideline. In analyses, the strong policy 
takes precedence over the guideline, so Arizona was not included stratified analyses including 
only guidelines. Washington implemented a guideline prior to the study period (2007) and 
implemented a strong policy during the study period (2012). Similar to Arizona, Washington was 
not included in the stratified analyses containing only guidelines. 
 






In addition to age and sex, a number of derived variables were included in the analysis. These 
include high baseline opioid use—defined as four indicator variables corresponding to the four 
MEDD thresholds used: 60 MEDD, 80 MEDD, 100 MEDD, and 120 MEDD—in at least one 
month prior to January 2012, which was the first policy implementation date. Time since first 
opioid prescription was also created to account for within-subject changes in MEDD. A number 
of indicators were created to account for patient populations that are explicitly excluded from 
some policies. These excluded patient groups, which were systematically identified in Chapter 2, 
include patients with cancer, acute pain, terminal/hospice/palliative patients, inpatients, and short 
courses of opioids. Patients were defined as acute pain or cancer if they had at least one relevant 
ICD9 code on either an inpatient or outpatient claim during the study period as defined by Mack 
et al.85 Patients with any inpatient claims during the study period were defined as inpatients, 
patients with any hospice facility codes, revenue codes, or a hospice discharge status during the 
study period were defined as terminal/hospice/palliative care. Patients with any emergency room 
or long-term care facility revenue or facility codes during the study period were defined as 
emergency room and long-term care facility patients, respectively. Any months in which there 
were no opioid prescriptions in the prior two months were considered short courses opioids, 




An interrupted time series with comparison states approach was used to evaluate the relationship 
between policy implementation and opioid use. First, generalized linear mixed models with a 
logit link were used with the dichotomous outcomes of any opioid use, MEDD>60 and 
MEDD>120 in the random sample of one million enrollees using dichotomous guideline and 





for age and sex, state fixed effects, a linear time trend, and clustering and the individual and state 
level, which accounts for correlated outcomes within states and individuals, were included. 
 
Among enrollees with any opioid use, generalized linear mixed models were used with MEDD 
as the primary outcome and person-month as the unit of analysis. All models included state fixed 
effects and clustering at the individual and state level, which account for outcomes within 
individuals and within states being correlated. Models included controls for age, sex, and months 
since the first opioid prescription. A linear time trend with a spline at January, 2014 was included 
based on plots of MEDD outcomes over time (Appendix Figures 1-4). Policy variables tested 
included both dichotomous and months in effect variables as described in the previous section. 
All time variables including months since first opioid prescription, months since policy 
implementation, and the monthly linear time trend were tested for multicollinearity, defined as 
variance inflation factors (VIF) >10. Models were stratified by all previously defined exclusion 
groups with the hypothesis that larger decreases in MEDD would be observed in the groups not 
excluded from the policies while excluded groups would see little to no change, relative to the 
control group. Models were also stratified by high baseline dose defined as at least month with a 
MEDD above each of the four designated thresholds prior to 2012. It was hypothesized that 
larger decreases in MEDD would be seen among individuals with high baseline use as compared 
to those without high baseline use. Individual regression analyses were also run for each state 
using both continuous and dichotomous MEDD outcomes according to each state’s policy 








Great care was taken to examine the opioid policy environment in the states and years selected 
for inclusion into the analysis. The greatest historical threat to validity identified was in 
Washington, which launched a PDMP within a month of the passage of its MEDD threshold 
legislative act. Therefore, analyses were conducted with and without Washington. All other 
PDMPs in control and treatment states became active outside of the study period. Among opioid 
users, the MEDD outcome was tested as continuous, log transformed, and dichotomous (60, 80, 
100, 120) and policy variables were also tested as dichotomous and months policy in effect to 
allow for the possibility of an implementation lag.  
 
Results 
Baseline—defined as months prior to January 2012—demographic, enrollment, and opioid use 
characteristics of a random sample of enrollees by policy state (control, guideline, or strong 
policy) are presented in Table 2. Of the one million individuals in the sample, 719,568 
individuals were enrolled prior to 2012 and are included in the baseline table. Demographic and 
enrollment characteristics were similar among all three groups with females comprising slightly 
more than half of enrollees, average age ranging from 30.67 (strong policy states) to 32.62 
(control states), and an average of 19.80 months (strong policy states) to 19.88 months of 
enrollment over two years. However, individuals in the strong policy states had higher opioid use 
at baseline with 19.29% of enrollees filling at least one opioid prescription prior to 2012 in 
strong policy states as compared to 15.89% in control states and 15.43% in guideline states. 
Similarly, enrollees in strong policy states were more likely to have filled at least one 






Among individuals with at least one opioid prescription during the study period, the final 
population for analysis was 27,391,637 person-months representing 7,030,785 individuals. Of 
these individuals, 4,961,599 had at least one opioid prescription filled prior to January 2012. 
Baseline characteristics of these users by policy state are presented in Table 3. In general, opioid 
users, regardless of policy state, were older and more likely to be female than the overall 
population of enrollees. As with the overall population of enrollees, baseline demographic 
characteristics of opioid users did not differ greatly by policy state. Opioid users in strong policy 
states were more likely than opioid users in control or guideline states to have high dose use 
defined as >60 MEDD ( 28.86% in strong policy states vs. 25.46% in control states and 25.28% 
in guideline states) and >120 MEDD (7.48% in strong policy states vs. 6.44% in guideline states 
and 6.45% in control states). In all policy states, a majority of opioid users had at least one 
exclusion—defined as an acute pain or cancer diagnosis, or hospice, inpatient, long-term care, or 
emergency department use during the study period, but opioid users in strong policy states were 
less likely to have one of these exclusions (56.96%) as compared to opioid users in guideline 
(58.62%) or control states (62.07%). 
 
Among all enrollees, the unadjusted proportion of a sample of enrollees receiving any opioid, 
opioids >60 MEDD, and opioids >120 MEDD decreased across all three policy groups over time 
(Figure 2). A higher proportion of enrollees in strong policy states received any opioids and high 
dose opioids than did enrollees in guideline and control states, but the proportion of enrollees 
with any opioid use appears to have decreased more rapidly in the strong policy states than in the 






Regression results using the dichotomous outcomes of any opioid use, MEDD>60, and 
MEDD>120 on a random sample of one million enrollees are presented in Table 4. Across all 
three outcomes, the odds of any opioid use and high dose opioid use decreased over time with 
0.6% lower odds of any opioid use, 0.9% lower odds of opioid use >60 MEDD and >120 MEDD 
each month. Passage of both guidelines and strong policies were associated with lower odds of 
any opioid use relative to control states. Guideline passage was associated with 15% lower odds 
of any opioid use (95% CI: 18% lower to 13% lower, p<0.001) and strong policy passage was 
associated with 15% lower odds of any opioid use (18% lower to 12% lower, p<0.001) relative 
to control states. However, neither guideline passage nor strong policy passage was associated 
with a change in odds of high dose use relative to control states.  
 
Several additional regression analyses were conducted among opioid users in treatment and 
control states. These included analyses using continuous, log transformed, and dichotomous 
MEDD outcomes and policy variables that allowed for lagged dissemination, and excluding 
Washington State. Results of these regressions are presented in Tables 1-8 of the Appendix. 
Among opioid users policy passage was associated with a small but statistically significant 
increase in MEDD (3.72 mg MEDD, 95% CI: 3.51, 3.92; p<0.001) (Appendix, Table 1). The 
direction and significance of this relationship did not change after excluding Washington State or 
from using different outcome and policy definitions. Each month the policy was in effect was 
associated with a 0.08 mg MEDD increase relative to control states, (95% CI: 0.07, 0.09; 






A number of stratified regression analyses were also conducted including separate analyses by 
policy type (guideline or strong policy) and exclusion groups. The results of these analyses are 
presented in Tables 9-32 of the Appendix and summarized in Figure 3. In each of the stratified 
analyses, the direction and significance of the relationship between policy and MEDD was 
consistent, although the magnitude of the relationship was larger in some excluded groups 
(hospice, cancer diagnosis, inpatient, long-term care) and smaller in other excluded groups (short 
courses of opioids and patients with acute pain diagnoses). Among patients with any exclusion, 
the policy was associated with a 3.10 mg MEDD increase relative to control states (95% CI: 
2.90, 3.31; p<0.001)(Appendix, Table 31) and among patients with no exclusions, the policy was 
associated with a 5.44 mg MEDD increase (95% CI: 4.92, 5.95; p<0.001). 
 
Individual regressions where each state was individually compared to control states were also 
performed. Due to reporting restrictions in the MarketScan© data use agreement, the results from 
individual states may not be presented. Therefore, a summary of state-level results are presented 
in Table 5. In guideline states, guideline passage was associated with increased odds of any 
opioid use in one state and decreased odds of any opioid use in three states. Similarly, in strong 
policy states, policy passage was associated with increased odds of any opioid use in one state 
and decreased odds of any opioid use in four states. However, when looking specifically at 
change in dose among opioid users, guideline passage was associated with increased MEDD in 
all states, regardless of outcome or exclusions. In strong policy states, the associations between 
policy passage and MEDD among opioid users were mixed. Policy passage was associated with 





with MEDD in the remaining three states. Results were also mixed when examining 
dichotomous outcomes and stratification by state-specific exclusion groups. 
 
Discussion 
Overall, both guidelines and strong policies were associated with lower odds of using opioids 
relative to control states. However, there was no statistically significant relationship between 
either type of policy and high dose opioid use. Among opioid users, there was actually a small, 
but statistically significant increase in dose, and excluding certain individuals for whom the 
policy was not specifically targeted did not change the magnitude or direction of the relationship. 
The small increase in dose may have been due to lower proportions of individuals receiving any 
opioids leaving only patients with higher pain management needs still receiving opioids. It is 
possible that MEDD thresholds as part of a larger set of opioid policies and accompanied by an 
increased awareness of the risks of opioid prescribing may have led to a decrease in the 
proportion of individuals prescribed opioids. However, there is no evidence that the policies 
successfully targeted high dose use or individuals with chronic, non-cancer pain. There was also 
no evidence that policies with a higher theorized impact—rules/regulations, legislative acts, and 
passive alert systems—had a greater impact on prescribed MEDD than did guidelines. Therefore, 
it is unlikely that any observed changes in overall opioid prescribing were due specifically to 
setting MEDD thresholds. 
 
This study had a number of important strengths, including a large, multi-state study population. 
This allowed for adequate sample size, even in the smallest sample subgroups, for example, 





of six years and includes pre- and post- periods for multiple policies of interest. The analysis 
improves upon prior evaluations of MEDD policies by making use of comparison states. This 
study also builds upon previous work which systematically examined policy structure, threshold 
level, and excluded groups and used this information to evaluate several different aspects of the 
policies. 
 
This study must also be evaluated in light of its limitations. From 2010 to 2016, the United States 
has experienced a complex and dynamic policy environment surrounding opioids. While care 
was taken to select states that did not pass major opioid legislation, MEDD policies, or 
implement PDMPs, policies at the local level were not systematically captured and may have had 
an influence in certain states. Individual insurers are also increasingly instituting a variety of 
coverage and utilization management policies to reduce high risk opioid use and some of these 
practices may include use of MEDD thresholds, which may bias the results. It is also important 
to note that only opioids from commercial claims covered by MarketScan© were observed. It 
was not possible to observe if individuals obtained opioids from other payers or sources.  
 
This study is an important first step in understanding how state-level MEDD policies may 
influence opioid prescribing in privately insured populations. Future work should evaluate the 
impact of MEDD policies in other contexts and populations. In particular, Medicaid prior 
authorization requirements which utilize MEDD thresholds have not been evaluated. In addition 
to evaluating the impact of MEDD policies on prescribing behavior, further research should 





differences in dissemination efforts and policy awareness and help understand why certain 







Table 1. Thresholds, policy types, and excluded patient groups in state policies 
State Threshold Policy Type Excluded patient groups 
AZ (03/14) 120 Legislative act Inpatients 
IN 60 Rule/Regulation Acute pain, terminal/hospice/palliative, 
long-term care facility, short courses  
RI 120 Rule/Regulation Acute pain 
TN 120 Passive alert system Acute pain, terminal/hospice/palliative, 
inpatient, emergency room 
WA (01/12) 120  Legislative act Acute pain 
AZ (11/14) 100 Guideline Acute pain and terminal/hospice/palliative 
patients, short courses  
CA 80 Guideline Acute pain, terminal/hospice/palliative 
CO 120 Guideline Cancer, terminal/hospice/palliative 
OH 80 Guideline Acute pain, terminal/hospice/palliative, 
short courses 
SC 80 Guideline None 
WA (04/07) 120 Guideline Acute pain, cancer 
 
 
Table 2. Baseline characteristics of all users by policy type (Random sample of enrollees, months 
prior to January 2012, N=719,568 enrollees) 




Strong Policy States 
(N=162,975) 
Male, N(%) 96,058 (49.66) 178,359 (49.11) 80,056 (49.12) 
Age, Mean (SD) 32.62 (18.27) 31.36 (18.30) 30.67 (18.46) 
Any opioid use, N(%) 30,740 (15.89) 56,044 (15.43) 31,432 (19.29) 
≥1 month >60 MEDD 7,698 (3.98) 14,324 (3.94) 9,058 (5.56) 
≥1 month >120 MEDD 1,978 (1.02) 3,703 (1.02) 2,328 (1.43) 






Table 3. Baseline characteristics of opioid users by policy type (Individuals using opioids prior to January 2012, N=4,961,599 
enrollees) 




Strong Policy States 
(N=1,318,303) 
Male, N(%) 575,690 (44.72) 1,034,102 (43.89) 575,835 (43.68) 
Age, Mean (SD) 40.30 (15.52) 40.22 (15.44) 39.94 (15.80) 
≥1 month >60 MEDD, N(%) 327,737 (25.46) 595,474 (25.28) 380,447 (28.86) 
≥1 month >120 MEDD, N(%) 82,971 (6.45) 151,763 (6.44) 98,549 (7.48) 
Months with ≥1 opioid, Mean (SD) 3.29 (5.48) 3.55 (5.95) 3.66 (5.96) 
Acute pain diagnosis, N(%) 448,458 (34.84) 749,220 (31.80) 394,538 (29.93) 
Cancer diagnosis, N(%) 206,204 (16.02) 355,930 (15.11) 187,757 (14.24) 
Hospice, N(%) 4,058 (0.32) 5,712 (0.24) 3,883 (0.29) 
Inpatient visit, N(%) 197,693 (15.36) 354,727 (15.06) 191,035 (14.49) 
Long-term care, N(%) 5,852 (0.45) 8,255 (0.35) 3,777 (0.29) 
ED visit, N(%) 388,058 (30.14) 616,931 (26.19) 350,476 (26.59) 
Any person-level exclusion, N(%) 799,066 (62.07) 1,381,147 (58.62) 750,952 (56.96) 






Table 4. Regression results, random sample of enrollees (N=1,000,000 people)a 
 Any opioid use MEDD>60 MEDD>120 
 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Guideline 0.845 (0.822, 0.868) <0.001 0.946 (0.894, 1.006) 0.078 0.984 (0.893, 1.084) 0.741 
Strong Policy 0.847 (0.818, 0.877)  <0.001 1.034 (0.962, 1.112) 0.367 1.033 (0.909 , 1.174) 0.623 
Age 1.040 (1.039, 1.040) <0.001 1.042 (1.040, 1.044) <0.001 1.043 (1.040, 1.046) <0.001 
Male 0.848 (0.827, 0.870) <0.001 0.916 (0.870, 0.963) <0.001 0.944 (0.864, 1.032) 0.208 
Monthsb 0.994 (0.994, 0.994) <0.001 0.991  (0.990, 0.992) <0.001 0.991 (0.989, 0.992) <0.001 
aIncludes state fixed effects and clustering at the individual and state level 






Table 5. Summary of state-level regressions 











OR, any opioid useb (0.67, 1.20)  1,3,0 (0.47, 1.05) 1,4,0 
Change in MEDDc (3.31, 8.2)  4,0,0 (-1.4, 5.5)  1,1,3 
OR, dichotomousc (1.04, 1.38)  4,0,0 (0.90, 1.28)  1,1,3 
OR, excludedd (1.04, 1.32)  4,0,0 (0.87, 1.23)  1,2,2 
OR, targetedd (1.01, 1.12)  3,0,0 (0.93, 1.30)  2,1,2 
aNumber of states with significant increases in MEDD, significant decreases in MEDD, and not statistically 
significant coefficients, respectively 
bRandom sample of one million enrollees from control and treatment states 
cAll opioid users from control and treatment states 
dUsing state-specific exclusions outlined in Table 1. South Carolina’s policy had no exclusions, and is therefore not 






Figure 1. Policy implementation timeline 
 Policy 2010 2011 2012 2013 2014 2015 
AZ Stronga                  X  X     
IN Strong                    X     
RI Strong                     X    
TN Strong                   X      
WA Strongb         X                
CA Guideline                    X     
CO Guideline                   X      
OH Guideline              X           
SC Guideline                    X     
VA Control                         
WI Control                         
aHad other policy (legislative act) and then guideline 







Figure 2. Percent of random sample of enrollees with any opioid use, MEDD>120, and 








Figure 3. Summary of regression coefficients for any policy in effect in stratified analyses, 








Appendix 1. MarketScan quantity cleaning protocol 
Relative frequencies of the quantity variable for prescription opioids was examined by year. 
Multiplier of ten quantity errors were present in all years, with errors more common beginning 
January, 2013. Frequencies of quantity were ranked pre- and post- 2013. Any quantity variable 
that, prior to 2013, was less frequent than the frequency of the quantity divided by ten was 
deemed to be incorrect. For example, 30 occurred more frequently than 300, so all 300 quantities 
were corrected to 30. The quantity 180, by contrast, occurred more frequently than the quantity 
18 and was not corrected. The following values were corrected: 
Original quantity variable Corrected quantity variable 
1-99, 101-121 No change 
140, 150, 160, 200, 210, 280, 300, 350, 400, 
450, 500, 560, 600, 750, 840, 900, 1200, 
1800, 2400, 2700, 3600 
Original quantity divided by 10 
2000, 3000, 4000, 6000, 9000, 12000 Original quantity divided by 100 
30000, 60000, 90000, 120000 Original quantity divided by 1000 
300000, 600000, 900000, 1200000 Original quantity divide by 10,000 
All other quantities <1000 No change 




























Table 1. Regression results, continuous MEDD outcome, any policy dichotomous, all patients 
(N=27,419,213 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.72 (3.51, 3.92) <.001 
Age 0.25 (0.24, 0.25) <.001 
Male 6.65 (6.56, 6.74) <.001 
Months after Jan 2010 -0.42 (-0.43, -0.42) <.001 
Months after Jan 2014 0.49 (0.47, 0.50) <.001 
Months since first opioid rx 0.63 (0.63, 0.63) <.001 
 
Table 2. Regression results, continuous MEDD outcome, any policy dichotomous, all states 
excluding Washington (N=26,008,150 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.76 (3.54, 3.97) <.001 
Age 0.25 (0.25, 0.26) <.001 
Male 6.74 (6.64, 6.83) <.001 
Months after Jan 2010 -0.43 (-0.43, -0.43) <.001 
Months after Jan 2014 0.50 (0.48, 0.51) <.001 
Months since first opioid rx 0.64 (0.63, 0.64) <.001 
 
Table 3. Regression results, logMEDD outcome, any policy dichotomous, all patients 
(N=27,409,820 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 0.02 (0.02, 0.02) <.001 
Age 0.00 (0.00, 0.00) <.001 
Male 0.06 (0.06, 0.06) <.001 
Months after Jan 2010 -0.00 (-0.00, -0.00) <.001 
Months after Jan 2014 0.01 (0.01, 0.01) <.001 






Table 4. Regression results, continuous MEDD outcome, months policy in effect, all patients 
(N=27,419,213 person-months) 
 
Variable Estimate 95% CI p-value 
Months policy in effect 0.08 (0.07, 0.09) <.001 
Age 0.25 (0.24, 0.25) <.001 
Male 6.65 (6.56, 6.74) <.001 
Months after Jan 2010 -0.41 (-0.42, -0.41) <.001 
Months after Jan 2014 0.56 (0.55, 0.58) <.001 
Months since first opioid rx 0.63 (0.63, 0.63) <.001 
 
Table 5. Regression results, MEDD >120 outcome, any policy dichotomous, all patients 
(N=27,419,213 person-months) 
 
Variable Estimate 95% CI p-value 
Policy Dichotomous 0.06 (0.06, 0.07) <.001 
Age 0.00 (0.00, 0.00) <.001 
Male 0.24 (0.24, 0.24) <.001 
Months after Jan 2010 -0.02 (-0.02, -0.02) <.001 
Months after Jan 2014 0.01 (0.01, 0.01) <.001 
Months since first opioid rx 0.03 (0.03, 0.03) <.001 
 
Table 6. Regression results, MEDD >100 outcome, any policy dichotomous, all patients 
(N=27,419,213 person-months) 
 Variable Estimate 95% CI p-value 
Policy Dichotomous 0.07 (0.06, 0.07) <.001 
Age 0.00 (0.00, 0.00) <.001 
Male 0.21 (0.21, 0.21) <.001 
Months after Jan 2010 -0.02 (-0.02, -0.02) <.001 
Months after Jan 2014 0.01 (0.01, 0.01) <.001 





Table 7. Regression results, MEDD >80 outcome, any policy dichotomous, all patients 
(N=27,419,213 person-months) 
 
 Variable Estimate 95% CI p-value 
Policy Dichotomous 0.07 (0.07, 0.07) <.001 
Age 0.01 (0.01, 0.01) <.001 
Male 0.17 (0.17, 0.18) <.001 
Months after Jan 2010 -0.02 (-0.02, -0.02) <.001 
Months after Jan 2014 0.02 (0.02, 0.02) <.001 
Months since first opioid rx 0.02 (0.02, 0.02) <.001 
 
Table 8. Regression results, MEDD >60 outcome, any policy dichotomous, all patients 
(N=27,419,213 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 0.04 (0.04, 0.04) <.001 
Age 0.01 (0.00, 0.01) <.001 
Male 0.14 (0.14, 0.14) <.001 
Months after Jan 2010 -0.01 (-0.01, -0.01) <.001 
Months after Jan 2014 0.02 (0.02, 0.02) <.001 
Months since first opioid rx 0.01 (0.01, 0.02) <.001 
 
Table 9. Regression results, continuous MEDD outcome, dichotomous policies, strong policies 
and control states only (N=10,173,845 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 1.54 (1.28, 1.80) <.001 
Age 0.23 (0.22, 0.23) <.001 
Male 6.94 (6.82, 7.06) <.001 
Months after Jan 2010 -0.37 (-0.38, -0.37) <.001 
Months after Jan 2014 0.30 (0.29, 0.32) <.001 




Table 10. Regression results, continuous MEDD outcome, dichotomous policies, guidelines and 
control states only (N=15,550,261 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 2.81 (2.59, 3.02) <.001 
Age 0.29 (0.28, 0.29) <.001 
Male 5.01 (4.91, 5.11) <.001 
Months after Jan 2010 -0.40 (-0.40, -0.39) <.001 
Months after Jan 2014 0.64 (0.62, 0.65) <.001 
Months since first opioid rx 0.61 (0.60, 0.61) <.001 
 
 
Table 11. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
high baseline use (>60 MEDD) (N=8,383,924 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -1.18 (-1.95, -0.42) 0.003 
Age 0.11 (0.10, 0.12) <.001 
Male 16.06 (15.80, 16.32) <.001 
Months after Jan 2010 -1.63 (-1.65, -1.60) <.001 
Months after Jan 2014 0.06 (0.01, 0.12) 0.017 
Months since first opioid rx 1.66 (1.64, 1.68) <.001 
 
 
Table 12. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
no high baseline use (>60 MEDD) (N=10,977,814 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -0.01 (-0.10, 0.09) 0.885 
Age -0.03 (-0.03, -0.03) <.001 
Male 0.86 (0.83, 0.89) <.001 
Months after Jan 2010 0.37 (0.36, 0.37) <.001 
Months after Jan 2014 0.15 (0.14, 0.15) <.001 




Table 13. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
high baseline use (>80 MEDD) (N=6,153,112 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -1.26 (-2.28, -0.24) 0.016 
Age 0.12 (0.10, 0.13) <.001 
Male 19.99 (19.65, 20.34) <.001 
Months after Jan 2010 -1.55 (-1.58, -1.52) <.001 
Months after Jan 2014 -0.11 (-0.18, -0.04) 0.002 
Months since first opioid rx 1.54 (1.51, 1.58) <.001 
 
Table 14. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
no high baseline use (>80 MEDD) (N=13,208,626 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -0.14 (-0.24, -0.05) 0.003 
Age -0.03 (-0.03, -0.03) <.001 
Male 0.93 (0.90, 0.96) <.001 
Months after Jan 2010 0.30 (0.30, 0.31) <.001 
Months after Jan 2014 0.21 (0.21, 0.22) <.001 
Months since first opioid rx -0.12 (-0.12, -0.11) <.001 
 
 
Table 15. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
high baseline use (>100) (N=4,536,037 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -0.47 (-1.82, 0.89) 0.497 
Age 0.27 (0.25, 0.29) <.001 
Male 23.22 (22.77, 23.68) <.001 
Months after Jan 2010 -1.25 (-1.30, -1.21) <.001 
Months after Jan 2014 -0.26 (-0.35, -0.17) <.001 





Table 16. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
no high baseline use (>100) (N=14,825,701 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -0.04 (-0.14, 0.06) 0.419 
Age -0.01 (-0.02, -0.01) <.001 
Male 1.05 (1.02, 1.08) <.001 
Months after Jan 2010 0.22 (0.22, 0.22) <.001 
Months after Jan 2014 0.29 (0.28, 0.30) <.001 
Months since first opioid rx -0.08 (-0.08, -0.08) <.001 
 
Table 17. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
high baseline use (>120) (N=3,711,471 person-months) 
 Variable Estimate 95% CI p-value 
Policy Dichotomous 0.32 (-1.30, 1.94) 0.699 
Age 0.41 (0.39, 0.44) <.001 
Male 24.52 (23.97, 25.08) <.001 
Months after Jan 2010 -1.08 (-1.14, -1.03) <.001 
Months after Jan 2014 -0.45 (-0.56, -0.34) <.001 
Months since first opioid rx 0.94 (0.89, 1.00) <.001 
   
Table 18. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
no high baseline use (>120) (N=15,650,267 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous -0.07 (-0.17, 0.03) 0.148 
Age -0.01 (-0.01, -0.00) <.001 
Male 1.09 (1.06, 1.13) <.001 
Months after Jan 2010 0.15 (0.15, 0.16) <.001 
Months after Jan 2014 0.32 (0.31, 0.33) <.001 






Table 19. Regression results, continuous MEDD outcome, any policy dichotomous, short opioid 
courses only (N=17,544,583 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 2.26 (2.08, 2.43) <.001 
Age 0.19 (0.19, 0.19) <.001 
Male 2.00 (1.93, 2.08) <.001 
Months after Jan 2010 -0.22 (-0.22, -0.22) <.001 
Months after Jan 2014 0.41 (0.40, 0.42) <.001 
Months since first opioid rx -0.07 (-0.07, -0.06) <.001 
 
Table 20. Regression results, continuous MEDD outcome, any policy dichotomous, excluding 
short opioid courses (N=9,874,630 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 6.14 (5.67, 6.60) <.001 
Age -0.48 (-0.49, -0.47) <.001 
Male 11.59 (11.38, 11.80) <.001 
Months after Jan 2010 -0.53 (-0.54, -0.52) <.001 
Months after Jan 2014 1.03 (0.99, 1.06) <.001 
Months since first opioid rx 0.40 (0.39, 0.41) <.001 
 
Table 21. Regression results, continuous MEDD outcome, any policy dichotomous, acute 
patients only (N=9,040,356 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.38 (3.03, 3.73) <.001 
Age 0.39 (0.39, 0.40) <.001 
Male 5.56 (5.40, 5.72) <.001 
Months after Jan 2010 -0.42 (-0.43, -0.42) <.001 
Months after Jan 2014 0.51 (0.48, 0.53) <.001 






Table 22. Regression results, continuous MEDD outcome, any policy dichotomous, excluding 
acute patients (N=18,378,857 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.90 (3.65, 4.16) <.001 
Age 0.16 (0.16, 0.17) <.001 
Male 7.37 (7.26, 7.48) <.001 
Months after Jan 2010 -0.43 (-0.43, -0.42) <.001 
Months after Jan 2014 0.48 (0.46, 0.49) <.001 
Months since first opioid rx 0.64 (0.64, 0.65) <.001 
 
Table 23. Regression results, continuous MEDD outcome, any policy dichotomous, cancer 
patients only (N=4,584,198 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 4.19 (3.61, 4.76) <.001 
Age 0.17 (0.16, 0.18) <.001 
Male 6.97 (6.71, 7.23) <.001 
Months after Jan 2010 -0.45 (-0.46, -0.44) <.001 
Months after Jan 2014 0.59 (0.55, 0.63) <.001 
Months since first opioid rx 0.57 (0.56, 0.58) <.001 
 
Table 24. Regression results, continuous MEDD outcome, any policy dichotomous, excluding 
cancer patients (N=22,835,015 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.61 (3.40, 3.83) <.001 
Age 0.24 (0.24, 0.24) <.001 
Male 6.73 (6.63, 6.83) <.001 
Months after Jan 2010 -0.42 (-0.42, -0.41) <.001 
Months after Jan 2014 0.47 (0.45, 0.48) <.001 




   
Table 25. Regression results, continuous MEDD outcome, any policy dichotomous, hospice 
patients only (N=142,049 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 15.72 (8.96, 22.48) <.001 
Age -1.16 (-1.33, -0.99) <.001 
Male 15.56 (12.69, 18.43) <.001 
Months after Jan 2010 -0.57 (-0.69, -0.44) <.001 
Months after Jan 2014 -0.14 (-0.63, 0.36) 0.589 
Months since first opioid rx 1.23 (1.11, 1.36) <.001 
 
Table 26. Regression results, continuous MEDD outcome, any policy dichotomous, excluding 
hospice patients (N=27,277,164 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.62 (3.42, 3.82) <.001 
Age 0.23 (0.23, 0.24) <.001 
Male 6.58 (6.49, 6.67) <.001 
Months after Jan 2010 -0.42 (-0.43, -0.42) <.001 
Months after Jan 2014 0.49 (0.48, 0.51) <.001 
Months since first opioid rx 0.63 (0.63, 0.63) <.001 
 
Table 27. Regression results, continuous MEDD outcome, any policy dichotomous, inpatient 
only (N=4,575,387 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 4.63 (4.06, 5.20) <.001 
Age 0.28 (0.27, 0.29) <.001 
Male 9.76 (9.50, 10.02) <.001 
Months after Jan 2010 -0.51 (-0.52, -0.50) <.001 
Months after Jan 2014 0.49 (0.45, 0.53) <.001 





Table 28. Regression results, continuous MEDD outcome, any policy dichotomous, excluding 
inpatient (N=22,843,826 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.57 (3.36, 3.79) <.001 
Age 0.21 (0.21, 0.21) <.001 
Male 6.56 (6.46, 6.66) <.001 
Months after Jan 2010 -0.40 (-0.41, -0.40) <.001 
Months after Jan 2014 0.46 (0.45, 0.48) <.001 
Months since first opioid rx 0.60 (0.60, 0.61) <.001 
 
Table 29. Regression results, continuous MEDD outcome, any policy dichotomous, long-term 
patients only (N=214,602 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 8.56 (5.95, 11.18) <.001 
Age -1.00 (-1.09, -0.92) <.001 
Male 9.82 (8.58, 11.05) <.001 
Months after Jan 2010 -0.68 (-0.74, -0.63) <.001 
Months after Jan 2014 0.17 (-0.01, 0.36) 0.069 
Months since first opioid rx 0.81 (0.76, 0.85) <.001 
   
 
Table 30. Regression results, continuous MEDD outcome, any policy dichotomous, excluding 
long-term patients (N=27,204,611 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.68 (3.48, 3.89) <.001 
Age 0.24 (0.24, 0.24) <.001 
Male 6.66 (6.57, 6.75) <.001 
Months after Jan 2010 -0.42 (-0.42, -0.42) <.001 
Months after Jan 2014 0.49 (0.47, 0.50) <.001 






Table 31. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
any exclusions (N=20,377,456 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 3.10 (2.90, 3.31) <.001 
Age 0.32 (0.32, 0.32) <.001 
Male 3.39 (3.30, 3.48) <.001 
Months after Jan 2010 -0.33 (-0.33, -0.32) <.001 
Months after Jan 2014 0.40 (0.39, 0.42) <.001 
Months since first opioid rx 0.36 (0.35, 0.36) <.001 
 
Table 32. Regression results, continuous MEDD outcome, any policy dichotomous, patients with 
no exclusions (N=7,041,757 person-months) 
Variable Estimate 95% CI p-value 
Policy Dichotomous 5.44 (4.92, 5.95) <.001 
Age -0.56 (-0.57, -0.55) <.001 
Male 11.51 (11.28, 11.74) <.001 
Months after Jan 2010 -0.49 (-0.50, -0.48) <.001 
Months after Jan 2014 1.00 (0.96, 1.04) <.001 








Summary of Results and Future Work 
Morphine Equivalent Daily Dose (MEDD) policies have been proposed as a tool for decreasing 
high dose prescribing, an important risk factor for opioid overdose. This dissertation examines 
the variation in state-level MEDD policies and evaluates their impact on prescribed dose in 
workers’ compensation and privately insured populations.  
 
In Chapter 2, state-level MEDD threshold policies were systematically identified and 
characterized on several categories including: state, agency/organization, policy type, effective 
date, threshold level, and policy exceptions. As of June 2017, 22 states had implemented 31 
MEDD threshold policies, with several states implementing multiple policies.  The most 
common type of policies were guidelines (14 states) followed by prior authorization 
requirements (4 states), rules/regulations (4 states), legislative acts (3 states), claim denials (2 
states), and alert systems/automatic patient reports (2 states). There were a wide range of 
threshold values (30-300 mg MEDD) with threshold levels generally decreasing over time. The 
first types of policies implemented were most commonly guidelines while more restrictive types 
of policies, such as prior authorization and claim denial, were implemented in later years. 
Policies frequently recognized the need to exclude certain patient groups, most commonly 
patients with terminal illnesses or acute pain. Many policies allowed that dose thresholds may be 






In Chapter 3, two workers’ compensation guidelines identified in Chapter 2 were evaluated using 
workers’ compensation claims data from a large, national insurer. Both pre- and post-policy data 
were available for the guideline states—Massachusetts and Connecticut—as well as three control 
states allowing for an interrupted time series with comparison states design. Guideline passage 
was associated with an 11% decrease in prescribed MEDD and larger decreases were observed in 
claimants with chronic, non-cancer pain and high dose opioid use at baseline. Larger decreases 
were also seen in Massachusetts as compared to Connecticut, possibly due to differences in 
dissemination. 
 
In Chapter 4, additional policies identified in Chapter 2, comprised of guidelines, 
rules/regulations, legislative acts, and passive alert systems, were evaluated using a large, 
nationally representative sample of commercial claims data. An interrupted time series with 
comparison states design was employed with opioid utilization outcomes. Additional stratified 
analyses conducted among opioid users examined each state policy individually and evaluated 
the policies separately by groups explicitly excluded by the policies (patients with cancer, acute 
pain diagnoses, hospice, inpatient or long-term care facility use and short courses of opioids) to 
determine if the policies were being targeted as intended. Policy implementation was associated 
with 15% lower odds of any opioid use among enrollees, but no significant change in the odds of 
receiving high dose prescriptions, specifically. In the population of opioid users, there was 
actually a small increase in prescribed dose. Furthermore, changes in opioid use did not appear to 
be targeted towards intended groups of patients with increased MEDD associated with policy 





Overall, a major finding of this study is that states have implemented a number of MEDD 
threshold policies, but there is no consensus as to how these policies should be structured. In the 
context of a workers’ compensation population, passage of MEDD threshold guidelines was 
associated with a decrease in prescribed MEDD. However, passage of MEDD threshold policies 
was not associated with a decrease in prescribed MEDD in a privately insured population. It is 
possible that guidelines targeted towards a specific population, e.g., injured workers, may be 
more effective than those aimed at the general population. This work builds on previous work by 
comprehensively identifying and characterizing MEDD threshold policies and by evaluating 
these types of policies in states outside of Washington and in privately insured populations.  
 
As a whole, this research had a number of important strengths. Chapter 2 provided a systematic 
review of state-level MEDD policies and characterized several important aspects of these 
policies, including sponsoring agency, date implemented, and excluded patient groups. This 
research laid the groundwork for the evaluations of MEDD policies conducted in Chapters 3 and 
4, as well as for future research on additional state-level MEDD policies. For example, the 
results of Chapter 2 informed the selection of control and treatment states in Chapters 3 and 4 as 
well as sensitivity analyses stratifying by relevant clinical subgroups. The evaluations in 
Chapters 3 and 4 also made use of sizeable patient populations with longitudinal data from 
multiple states. This data allowed for an interrupted time series with a comparison group study 
design, a superior design to previous evaluations which did not utilize comparison states. 
 
This research also had a number of important limitations. Chapter 2 did not systematically 




behavior. Certain policy characteristics, such as dissemination and enforcement efforts, were not 
systematically collected and limit the conclusions that may be drawn about the changes in 
prescribing observed in Chapters 3 and 4. Claims data were used to evaluate a subset of policies 
and these data include several important limitations. Namely, these data only contain information 
on opioids obtained through the insurer and lack information on pain ratings and detailed 
medical history. The evaluations of MEDD policy in Chapters 3 and 4 must also be interpreted in 
light of the complex and rapidly changing policy environment surrounding opioids in the years 
since Washington implemented its MEDD guidelines in 2007. While careful selection of 
treatment and control states mitigated some historical threats to the study, policy changes at the 
local or individual insurer level may have influenced MEDD in ways that were not taken into 
account. The generalizability of these evaluations should also be taken into consideration. In 
particular, the evaluation of workers’ compensation policies only examined two states and one 
workers’ compensation insurer. 
 
Future work should seek to determine why MEDD threshold policies may work in some 
contexts, but not others and examine the impact of MEDD threshold policies in other 
populations, including impacts on patient health outcomes. This may include surveys or 
qualitative work understanding how policies influence prescriber behavior in practice. For 
example, a survey of prescribers in states which passed guidelines evaluating their knowledge of 
the guidelines could help illustrate the mechanisms through which guidelines influence (or fail to 





MEDD policies should also be evaluated in other contexts and populations. In particular, data 
were not available for this study to evaluate the impact of prior authorization or claim denial 
MEDD policies, which may have a greater impact on prescribing behavior than the other types of 
policies studied—namely guidelines, rules/regulations, legislation, and automatic alerts/patient 
reports. For example, Medicaid has implemented prior authorization and claim denial based on 
MEDD. The impact of MEDD policies on patient outcomes is also important, particularly among 
policies that were shown to be associated with changes in provider behavior. 
 
Future research should also investigate whether reducing prescribed dose has any unintended 
consequences. One unintended consequence of concern is that patients who would have 
otherwise received high doses of opioids may not be receiving adequate pain treatment or may 
experience withdrawal symptoms leading to the use of heroin or other illegal sources of opioid 
drugs. Better understanding these pathways of opioid use and developing adequate support for 
patients to manage their pain through other means such as cognitive behavioral therapy or non-
opioid medications should be a research priority. 
 
Policy, Practice, and Research Implications 
For policymakers interested in implementing MEDD threshold policies, there are a number of 
different options from guidelines to legislative acts to prior authorization requirements to 
consider. The compendium of policies presented in Chapter 2 will allow policymakers to review 
what has been done in other states and highlights important patient groups that should be 





Disseminating MEDD guidelines to doctors who treat workers’ compensation cases may reduce 
high-dose opioid prescribing: an important risk factor for opioid-related mortality, while still 
allowing for autonomy in practice. Critically, MEDD guidelines would allow prescribers to use 
their clinical judgment to incorporate differences in drug formulations and individual pain 
management needs into their prescribing decisions. However, better understanding of MEDD, its 
calculation, and its limitations is necessary for these types of policies to have a positive impact. 
There are a growing number of resources available for providers to determine the overall MEDD 
prescribed to patients, such as online opioid calculators, but only a small number of policies 
automatically calculate MEDD and take into account multiple and overlapping prescriptions 
(e.g., states with alert systems/automatic reports). Improving provider education surrounding 
MEDD measurement and reducing the burden on providers to make these calculations and keep 
track of multiple prescriptions may be an important first step. 
 
As policymakers seek to adopt new prescribing guidelines, it is important to recognize that high-
dose opioid prescribing is only one risk factor for opioid mortality and a multi-pronged strategy 
that takes other risk factors into account, such as opioid diversion, days supply of drugs, and co-
use of other drugs such as alcohol or benzodiazepines, may be more appropriate. Critically, 
follow-up with patients who have tapered from high-dose prescribing is needed to ensure that 
these patients do not turn to other sources of drugs and receive adequate support managing their 
pain.  
 
Researchers may use the results of Chapter 2 to inform future evaluations of state-level MEDD 
policies. In particular, Medicaid policies and policies implemented after 2015 should be 




evaluation used in Chapters 3 and 4 can also be used in future claims-based evaluations of 
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